

=> fil reg; d stat que 138; d stat que 129
 FILE 'REGISTRY' ENTERED AT 13:16:46 ON 26 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2008 HIGHEST RN 1053064-22-4
 DICTIONARY FILE UPDATES: 25 SEP 2008 HIGHEST RN 1053064-22-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

ISCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

L4

STR



VAR G1=H/11/13/X

VAR G7=H/11/O

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 11

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED




NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L7 35801 SEA FILE=REGISTRY SSS FUL L4

L24

STR



```

VAR G1=H/11/13/X/COOH
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 11
CONNECT IS E2 RC AT 15
CONNECT IS E2 RC AT 32
CONNECT IS E1 RC AT 39
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 39



```

```

STEREO ATTRIBUTES: NONE
L37      869 SEA FILE=REGISTRY SUB=L7 SSS FUL L24
L38      304 SEA FILE=REGISTRY ABB=ON L37 AND 4/NR

```

L4 STR



```

VAR G1=H/11/13/X
VAR G7=H/11/O
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 11
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L7 35801 SEA FILE=REGISTRY SSS FUL L4

L22 STR



VAR G1=H/11/13/X/COOH

VAR G7=H/11/OH/22/24

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11

CONNECT IS E1 RC AT 23

CONNECT IS E2 RC AT 25

CONNECT IS E1 RC AT 27

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 11

DEFAULT ECLEVEL IS LIMITED




GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L24 STR



VAR G1=H/11/13/X/COOH

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11
 CONNECT IS E2 RC AT 15
 CONNECT IS E2 RC AT 32
 CONNECT IS E1 RC AT 39
 DEFAULT MLEVEL IS ATOM
 MLEVEL IS CLASS AT 11
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 39

STEREO ATTRIBUTES: NONE

L28 17584 SEA FILE=REGISTRY SUB=L7 SSS FUL (L24 OR L22)
 L29 8061 SEA FILE=REGISTRY ABB=ON L28 AND 2/NR

=> fil capl; d que nos l16; d que nos l18; d que nos l57; d que nos l41; d que nos l59

FILE 'CAPLUS' ENTERED AT 13:17:07 ON 26 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2008 VOL 149 ISS 14

FILE LAST UPDATED: 25 Sep 2008 (20080925/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L4 STR
 L7 35801 SEA FILE=REGISTRY SSS FUL L4
 L8 70589 SEA FILE=REGISTRY ABB=ON BI/ELS =COMPOUNDS CONTAINING BISMUTH
 L9 42497 SEA FILE=CAPLUS ABB=ON L7
 L10 162907 SEA FILE=CAPLUS ABB=ON L8
 L14 879 SEA FILE=CAPLUS ABB=ON L9(L)CAT/RL =CATALYST USE
 L15 6883 SEA FILE=CAPLUS ABB=ON L10(L)CAT/RL
 L16 9 SEA FILE=CAPLUS ABB=ON L14 AND L15

```

L4      STR
L7      35801 SEA FILE=REGISTRY SSS FUL L4
L8      70589 SEA FILE=REGISTRY ABB=ON BI/ELS
L9      42497 SEA FILE=CAPLUS ABB=ON L7
L10     162907 SEA FILE=CAPLUS ABB=ON L8
L11     389 SEA FILE=CAPLUS ABB=ON L9 AND L10
L17     81358 SEA FILE=CAPLUS ABB=ON POLYURETHANES/CT
L18     7 SEA FILE=CAPLUS ABB=ON L11 AND L17

```

```

L4      STR
L7      35801 SEA FILE=REGISTRY SSS FUL L4
L8      70589 SEA FILE=REGISTRY ABB=ON BI/ELS
L9      42497 SEA FILE=CAPLUS ABB=ON L7
L10     162907 SEA FILE=CAPLUS ABB=ON L8
L11     389 SEA FILE=CAPLUS ABB=ON L9 AND L10
L55     80804 SEA FILE=REGISTRY ABB=ON POLYURETHANE/PCT
L56     47561 SEA FILE=CAPLUS ABB=ON L55
L57     2 SEA FILE=CAPLUS ABB=ON L56 AND L11

```

```

L4      STR
L7      35801 SEA FILE=REGISTRY SSS FUL L4
L8      70589 SEA FILE=REGISTRY ABB=ON BI/ELS
L10     162907 SEA FILE=CAPLUS ABB=ON L8
L24     STR
L37     869 SEA FILE=REGISTRY SUB=L7 SSS FUL L24
L38     304 SEA FILE=REGISTRY ABB=ON L37 AND 4/NR
L39     253 SEA FILE=CAPLUS ABB=ON L38
L41     2 SEA FILE=CAPLUS ABB=ON L10 AND L39

```

```

L4      STR
L7      35801 SEA FILE=REGISTRY SSS FUL L4
L8      70589 SEA FILE=REGISTRY ABB=ON BI/ELS
L9      42497 SEA FILE=CAPLUS ABB=ON L7
L10     162907 SEA FILE=CAPLUS ABB=ON L8
L14     879 SEA FILE=CAPLUS ABB=ON L9(L)CAT/RL
L15     6883 SEA FILE=CAPLUS ABB=ON L10(L)CAT/RL
L17     81358 SEA FILE=CAPLUS ABB=ON POLYURETHANES/CT
L22     STR
L24     STR
L28     17584 SEA FILE=REGISTRY SUB=L7 SSS FUL (L24 OR L22)
L29     8061 SEA FILE=REGISTRY ABB=ON L28 AND 2/NR
L40     37837 SEA FILE=CAPLUS ABB=ON L29
L55     80804 SEA FILE=REGISTRY ABB=ON POLYURETHANE/PCT
L56     47561 SEA FILE=CAPLUS ABB=ON L55
L59     24 SEA FILE=CAPLUS ABB=ON L10 AND L40 AND (L14 OR L15 OR L17 OR
        L56)

```

```

=> s 116,118,157,141,159
L60     26 (L16 OR L18 OR L57 OR L41 OR L59)

```

```

=> d ibib abs hitind hitstr l60 1-26; fil hom

```

```

L60 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

```

ACCESSION NUMBER: 2008:1045633 CAPLUS Full-text
 DOCUMENT NUMBER: 149:309843
 TITLE: Novel catalyst and related hydrogenations
 INVENTOR(S): Bonrath, Werner; Grasmann, Martin; Renken, Albert;
 Semagina, Natalia; Kiwi-Minsker, Lioubov
 PATENT ASSIGNEE(S): DSM IP Assets B.V., Neth.
 SOURCE: PCT Int. Appl., 23pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008101603	A2	20080828	WO 2008-EP995	20080209
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2007-3423 A 20070219

AB The invention relates to a structured catalyst based on sintered metal fibers (SMF) coated by a ZnO layer impregnated with Pd-nanoparticles, reactions of organic starting material with hydrogen in the presence of the catalyst and vitamins, carotinoids, perfume ingredients, and/or food or feed ingredients prepared by using this reaction.

IC ICM B01J

CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)

IT 91-22-5, Quinoline, reactions

RL: RGT (Reagent); RACT (Reactant or reagent)
 (activity/selectivity enhancer; hydrogenation catalyst for methylbutynol based on sintered metal fibers coated by ZnO layer impregnated with Pd-nanoparticles)

IT 1314-13-2, Zinc oxide, uses 7439-92-1, Lead, uses 7439-96-5, Manganese, uses 7440-31-5, Tin, uses 7440-43-9, Cadmium, uses 7440-50-8, Copper, uses 7440-57-5, Gold, uses 7440-66-6, Zinc, uses 7440-63-9, Bismuth, uses

RL: CAT (Catalyst use); USES (Uses)
 (hydrogenation catalyst for methylbutynol based on sintered metal fibers coated by ZnO layer impregnated with Pd-nanoparticles)

IT 91-22-5, Quinoline, reactions

RL: RGT (Reagent); RACT (Reactant or reagent)
 (activity/selectivity enhancer; hydrogenation catalyst for methylbutynol based on sintered metal fibers coated by ZnO layer impregnated with Pd-nanoparticles)

RN 91-22-5 CAPLUS

CN Quinoline (CA INDEX NAME)



IT 7440-69-9, Bismuth, uses
 RL: CAT (Catalyst use); USES (Uses)
 (hydrogenation catalyst for methylbutynol based on sintered metal
 fibers coated by ZnO layer impregnated with Pd-nanoparticles)
 RN 7440-69-9 CAPLUS
 CN Bismuth (CA INDEX NAME)

Bi

L60 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:528331 CAPLUS Full-text
 DOCUMENT NUMBER: 148:518637
 TITLE: Method of producing flexible laminates
 Booth, Gregory E.; Johnson, Randy A.; Carlson, Gary
 M.; Harvey, Raymond S.; Moy, Thomas M.
 INVENTOR(S): Ashland Inc., USA
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 7pp.
 SOURCE: CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080099141	A1	20080501	US 2006-586499	20061026
WO 2008052134	A1	20080502	WO 2007-US82561	20071025
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-586499 A 20061026

AB A method of producing a flexible laminate and a flexible laminate produced by the method are provided. The method involves laminating flexible substrates with a urethane adhesive and allowing the urethane adhesive to cure. The urethane adhesive comprises at least one polyisocyanate, at least one polyfunctional curative, at least one metal based catalyst and a catalyst blocking agent. The catalyst blocking agent allows for improved control of the curing rate of the urethane adhesive in the flexible laminate. The curing rate of the urethane adhesive can be controlled with heat or actinic radiation or both. The method allows for faster and more economical production of flexible laminates.

INCL 156331700
 CC 38-3 (Plastics Fabrication and Uses)
 IT Polyurethanes, uses
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (method of producing flexible laminates)
 IT 56-36-0, Tri-n-butyltin acetate 77-58-7, Dibutyl tin dilaurate 301-10-0, Stannous octoate 595-90-4, Tetraphenyltin 638-39-1, Stannous acetate 753-73-1, Dimethyltin dichloride 1345-07-9, Bismuth sulfide 1461-25-2, Tetraethyltin 4731-77-5, Dibutyltin dioctoate 6493-69-2, Stannous citrate 7646-78-8, Stannic chloride, uses 7772-99-8, Stannous chloride, uses 10361-44-1, Bismuth nitrate 18282-10-5, Stannic oxide
 RL: CAT (Catalyst use); USES (Uses)
 (method of producing flexible laminates)
 IT 9048-90-2F, Hexamethylene diisocyanate-polypropylene glycol copolymer
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (method of producing flexible laminates)
 IT 75-50-3, Trimethylamine, uses 91-22-5, Quinoline, uses 98-94-2 100-37-8, Diethylethanolamine 100-74-3, N-Ethylmorpholine 102-69-2, Tripropylamine 102-71-6, Triethanolamine, uses 102-82-9, Tributylamine 103-83-3, Dimethylbenzylamine 108-01-0, Dimethylethanolamine 108-75-8, 2,4,6-Collidine 110-18-9 110-86-1, Pyridine, uses 119-65-3, Isoquinoline 121-44-8, Triethylamine, uses 280-57-9, Triethylenediamine 598-56-1, Dimethylethylamine 1344-28-1, Aluminum oxide, uses 2057-49-0, 4-Phenylpropylpyridine 7631-86-9, Silicon oxide, uses
 RL: MOA (Modifier or additive use); USES (Uses)
 (method of producing flexible laminates)
 IT 1345-07-9, Bismuth sulfide 10361-44-1, Bismuth nitrate
 RL: CAT (Catalyst use); USES (Uses)
 (method of producing flexible laminates)
 RN 1345-07-9 CAPLUS
 CN Bismuth sulfide (Bi2S3) (CA INDEX NAME)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 10361-44-1 CAPLUS
 CN Nitric acid, bismuth(3+) salt (3:1) (CA INDEX NAME)




● 1/3 Bi(III)

IT 9048-90-2P, Hexamethylene diisocyanate-polypropylene glycol copolymer
 RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (method of producing flexible laminates)
 RN 9048-90-2 CAPLUS
 CN Poly[oxy(methyl-1,2-ethanediyl)], α -hydro- ω -hydroxy-, polymer with 1,6-diisocyanatohexane (CA INDEX NAME)

CM 1
 CRN 25322-69-4
 CMF (C3 H6 O)n H2 O
 CCI IDS, PMS



CM 2
 CRN 822-06-0
 CMF C8 H12 N2 O2



IT 91-22-5, Quinoline, uses
 RL: MOA (Modifier or additive use); USES (Uses)
 (method of producing flexible laminates)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)



L60 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:127047 CAPLUS [Full-text](#)
 TITLE: Aliphatic and alicyclic aldehydes: synthesis by
 hydrolysis
 AUTHOR(S): Plietker, B.
 CORPORATE SOURCE: Organische Chemie II, Fachbereich Chemie der
 Universitaet Dortmund, Dortmund, 44221, Germany
 SOURCE: Science of Synthesis (2007), Volume Date 2006, 25,
 151-197
 CODEN: SSCYJ9
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review of methods to prepare aliphatic and alicyclic aldehydes by
 hydrolysis.
 CC 21-0 (General Organic Chemistry)
 IT INDEXING IN PROGRESS
 IT 64-18-6, Formic acid 75-18-3 75-36-5, Acetyl chloride 75-91-2
 77-78-1 87-90-1 91-22-5, Quinoline 104-15-4 108-48-5
 128-08-5 144-62-7, Ethanedioic acid 311-28-4 603-35-0 624-92-0
 1122-58-3 2712-78-9 3240-34-4 5872-08-2 6674-22-2 7440-66-6,
 Zinc 7447-39-4, Copper chloride (CuCl2) 7664-38-2, Phosphoric acid

7705-08-0, Iron chloride (FeCl3) 7761-88-8, Nitric acid silver(1+) salt
 (1:1) 7772-99-8, Tin chloride (SnCl2) 7787-60-2 7790-86-5,
 Cerium chloride (CeCl3) 7791-25-5, Sulfuryl chloride 10026-07-0
 10450-60-9, Periodic acid (H5IO6) 61717-82-6 79271-56-0 81408-56-2
 87413-09-0 125672-05-1
 RL: CAT (Catalyst use); USES (Uses)
 (review preparation of aliphatic and alicyclic aldehydes by hydrolysis)
 IT 91-22-5, Quinoline 7787-60-2
 RL: CAT (Catalyst use); USES (Uses)
 (review preparation of aliphatic and alicyclic aldehydes by hydrolysis)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)



RN 7787-60-2 CAPLUS
 CN Bismuthine, trichloro- (CA INDEX NAME)



REFERENCE COUNT: 347 THERE ARE 347 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L60 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2005:402546 CAPLUS Full-text
 DOCUMENT NUMBER: 142:451460
 TITLE: Makeup emulsions comprising nonionic and ionic
 surfactants and solid particles
 INVENTOR(S): Quemin, Eric
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1529513	A1	20050511	EP 2004-292494	20041020
EP 1529513	B1	20080305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
FR 2861986	A1	20050513	FR 2003-50810	20031107
FR 2861986	B1	20071214		
AT 387938	T	20080315	AT 2004-292494	20041020
JP 2005139189	A	20050602	JP 2004-322824	20041105
PRIORITY APPLN. INFO.:			FR 2003-50810	A 20031107

- AB Makeup emulsions comprise an oil phase dispersed in an aqueous phase contain (i) a nonionic surfactant and an ionic surfactant having dynamic interfacial tension ≤ 7 mNewton/m (ii) and solid particles that are dispersed in the aqueous phase. The makeup compns. are stable after storage at 45° for 2 mo. A nanoemulsion contained water 60.05, methylparaben 0.2, sorbitan tristearate 1, cetyl alc. 4.7, glyceryl stearate 3.9, polyethylene glycol stearate 2.22, hydrogenated polyisobutene 13.5, isononyl isononanoate 13.5, potassium cetyl phosphate 0.83, and propylparaben 0.1%.
- IC ICM A61K007-02
ICS A61K007-021; A61K007-025; A61K007-031; A61K007-032
- CC 62-4 (Essential Oils and Cosmetics)
- IT Fatty acids, biological studies
Fluoropolymers, biological studies
Hydrocarbon oils
Kaolin, biological studies
Mica-group minerals, biological studies
Oxides (inorganic), biological studies
Paraffin oils
Polyamides, biological studies
Polysiloxanes, biological studies
Polyurethanes, biological studies
Soaps
Vitamins
Waxes
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(makeup emulsions comprising nonionic and ionic surfactants agent and solid particles)
- IT Polyurethanes, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(polyoxyalkylene; makeup emulsions comprising nonionic and ionic surfactants agent and solid particles)
- IT 91-22-5, Quinoline, biological studies 92-83-1, Xanthene
129-00-0, Pyrene, biological studies 519-73-3, Triphenylmethane
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(dyes; makeup emulsions comprising nonionic and ionic surfactants agent and solid particles)
- IT 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 79-10-7D, Acrylic acid, polymers 112-85-6, Behenic acid 112-92-5, Stearyl alcohol 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 555-43-1, Glyceryl tristearate 555-44-2, Glyceryl tripalmitate 661-19-8, Behenyl alcohol 1306-06-5, Hydroxylapatite 1314-13-2, ZnO, biological studies 1314-23-4, Zirconium oxide, biological studies 1323-83-7, Glyceryl distearate 1390-65-4, Carmine 2090-64-4, Magnesium hydrogen carbonate 2421-33-2D, alkali salts 4028-10-8, Sodium palmitoyl sarcosinate 7631-86-9, Silica, biological studies 7787-59-9, Bismuth oxychloride 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-40-2, Carob gum 9002-84-0, Polytetrafluoroethylene 9002-88-4, Polyethylene 9002-89-5, Poly(vinyl alcohol) 9003-27-4D, Polyisobutene, hydrogenated 9003-39-8, Polyvinylpyrrolidone 9004-34-6, Cellulose, biological studies 9005-25-8, Starch, biological studies 9010-76-8, Acrylonitrile-vinylidene chloride copolymer 9011-16-9, Maleic anhydride-methyl vinyl ether copolymer 10043-11-5, Boron nitride, biological studies 11099-07-3, Glyceryl stearate 11118-57-3, Chromium oxide 11129-18-3, Cerium oxide 12227-89-3, Black iron oxide 12240-15-2, Ferric blue 12441-09-7D, Sorbitan, esters with fatty acids 13463-67-7, Titanium oxide, biological studies 14807-96-6, Talc, biological studies 17026-85-6, Potassium Cetyl phosphate 24937-14-2, Poly(β -alanine) 25086-89-9, Vinyl acetate-vinylpyrrolidone

copolymer 25513-34-2, Poly(β -alanine) 26657-95-4, Glyceryl
 dipalmitate 26657-96-5, Glyceryl monopalmitate 26658-19-5, Span 65 V
 31360-68-6 31566-31-1, Glyceryl monostearate 36653-82-4, Cetyl alcohol
 39464-87-4, Scleroglucan 42131-25-9, Isononyl isononanoate 51274-00-1,
 Yellow iron oxide 52357-70-7, Brown iron oxide 59409-41-5,
 Lauroyl-L-lysine 67167-59-3, Polyethylene glycol stearate 68651-46-7,
 Indigo (dye) 68814-13-1D, Cetyl phosphate, alkali salts 71010-52-1,
 Gellan 96949-21-2, Rhamsan gum 154530-80-0, SER-AD FX 1100
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (makeup emulsions comprising nonionic and ionic surfactants agent and
 solid particles)
 IT 91-22-5, Quinoline, biological studies
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (dyes; makeup emulsions comprising nonionic and ionic surfactants agent
 and solid particles)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)



IT 7787-59-9, Bismuth oxychloride
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (makeup emulsions comprising nonionic and ionic surfactants agent and
 solid particles)
 RN 7787-59-9 CAPLUS
 CN Bismuthine, chlorooxo- (CA INDEX NAME)

Cl-Bi=O

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:141200 CAPLUS Full-text
 DOCUMENT NUMBER: 142:254568
 TITLE: Methods and compositions for increasing the efficacy
 of biologically-active ingredients such as antitumor
 agents
 INVENTOR(S): Windsor, J. Brian; Roux, Stan J.; Lloyd, Alan M.;
 Thomas, Collin E.
 PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
 SOURCE: PCT Int. Appl., 243 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2005014777	A2	20050217	WO 2003-US32667	20031016

WO 2005014777 A3 20050915

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2502148 A1 20050217 CA 2003-2502148 20031016
AU 2003304398 A1 20050225 AU 2003-304398 20031016
EP 1576150 A2 20050921 EP 2003-816736 20031016
EP 1576150 A3 20051102

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 20060276339 A1 20061207 US 2006-531744 20060123
US 2002-418803P P 20021016
WO 2003-US32667 W 20031016

PRIORITY APPLN. INFO.:

AB The invention provides methods and compns. for modulating the sensitivity of cells to cytotoxic compds. and other active agents. In accordance with the invention, compns. are provided comprising combinations of ectophosphatase inhibitors and active agents. Active agents include antibiotics, fungicides, herbicides, insecticides, chemotherapeutic agents, and plant growth regulators. By increasing the efficacy of active agents, the invention allows use of compns. with lowered concns. of active ingredients.

IC ICM C12N

CC 1-6 (Pharmacology)

IT Polyurethanes, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Macroplast; methods and compns. for increasing efficacy of biol. active ingredients such as antitumor agents)

IT 99-26-3 99-30-9 99-76-3 99-96-7, biological studies
100-00-5 100-41-4, biological studies 100-44-7, biological studies
100-51-6, Benzenemethanol, biological studies 100-56-1 100-57-2
100-94-7D, acylamido alkyl derivs. 100-95-8 101-05-3 101-20-2
101-21-3 101-42-8 101-81-5 101-84-8D, tetrapropylene derivs., sulfonated, sodium salts 102-07-8 102-30-7 102-71-6D, copper hydroxide complexes 103-11-7 103-27-5 104-28-9 104-54-1 104-55-2
104-60-9 104-76-7 105-67-9 106-22-9 106-23-0 106-24-1
106-44-5, biological studies 106-46-7 106-48-9 106-88-7 106-93-4
106-96-7 106-97-8, Butane, biological studies 106-99-0, 1,3-Butadiene, biological studies 107-04-0 107-06-2, biological studies 107-18-6, 2-Propen-1-ol, biological studies 107-19-7, 2-Propyn-1-ol 107-26-6
107-27-7 107-31-3 107-49-3 107-64-2 108-05-4, Acetic acid ethenyl ester, biological studies 108-07-6 108-11-2 108-24-7 108-31-6, 2,5-Furandione, biological studies 108-39-4, biological studies
108-46-3, 1,3-Benzenediol, biological studies 108-80-5, 1,3,5-Triazine-2,4,6-(1H,3H,5H)-trione 108-83-8 108-88-3, biological studies 108-90-7, biological studies 108-93-0, Cyclohexanol, biological studies 108-94-1, Cyclohexanone, biological studies
108-95-2, Phenol, biological studies 109-62-6 109-66-0, Pentane, biological studies 109-69-3 109-76-2D, 1,3-Propanediamine, N-C12-18alkyl derivs. 109-76-2D, 1,3-Propanediamine, N-C15-18alkyl derivs., diacetate 109-76-2D, 1,3-Propanediamine, N-C6-18alkyl derivs., acetate 109-76-2D, 1,3-Propanediamine, N-alkyl derivs. 109-76-2D, 1,3-Propanediamine, N-alkyl derivs. hydrochloride 109-76-2D,

1,3-Propanediamine, N-alkyl derivs., propionate-copper complex
 109-76-2D, 1,3-Propanediamine, N-alkyl derivs., salts 109-76-2D,
 1,3-Propanediamine, N-coco-alkyl derivs., adipate 109-76-2D,
 1,3-Propanediamine, N-coco-alkyl derivs., hydroxyacetate 109-76-2D,
 1,3-Propanediamine, N-coco-alkyl derivs., monobenzoate 109-79-5,
 1-Butanethiol 109-94-4 109-99-9, biological studies 110-12-3
 110-17-8, 2-Butenedioic acid (2E)-, biological studies 110-19-0
 110-43-0, 2-Heptanone 110-54-3, Hexane, biological studies 110-66-7,
 1-Pentanethiol 110-80-5 110-82-7, Cyclohexane, biological studies
 110-88-3, 1,3,5-Trioxane, biological studies 111-01-3 111-20-6,
 Decanedioic acid, biological studies 111-27-3, 1-Hexanol, biological
 studies 111-70-6, 1-Heptanol 111-76-2 111-77-3 111-87-5,
 1-Octanol, biological studies 111-90-0 111-98-8 112-02-7 112-05-0,
 Nonanoic acid 112-30-1, 1-Decanol 112-31-2, Decanal 112-34-5
 112-44-7, Undecanal 112-53-8, 1-Dodecanol 112-54-9, Dodecanal
 112-62-9 112-72-1, 1-Tetradecanol 112-92-5, 1-Octadecanol 113-98-4
 114-26-1 115-07-1, 1-Propene, biological studies 115-10-6 115-28-6
 115-29-7 115-31-1 115-32-2 115-90-2 115-93-5 116-01-8 116-02-9
 116-06-3 116-16-5 116-25-6 116-52-9 117-52-2 117-81-7 117-84-0
 118-34-3 118-52-5 118-56-9 118-74-1 119-12-0 119-38-0 120-23-0
 120-32-1 120-39-8 120-47-8 120-72-9, 1H-Indole, biological studies
 120-78-5 120-82-1 120-83-2 120-94-5 121-20-0 121-21-1 121-29-9
 121-33-5 121-54-0 121-75-5 122-10-1 122-14-5 122-15-6 122-19-0
 122-34-9 122-37-2 122-39-4, biological studies 122-42-9 122-64-5
 122-70-3 122-97-4, Benzenepropanol 123-17-1 123-33-1 123-35-3
 123-66-0 123-88-6 123-91-1, 1,4-Dioxane, biological studies
 123-92-2 124-03-8 124-07-2, Octanoic acid, biological studies
 124-13-0, Octanal 124-16-3 124-25-4, Tetradecanal 124-38-9, Carbon
 dioxide, biological studies 124-48-1 124-58-3 124-65-2 125-67-7
 125-84-8 126-06-7 126-07-8 126-22-7 126-73-8, Phosphoric acid
 tributyl ester, biological studies 126-75-0 126-94-3 127-07-1
 127-18-4, biological studies 127-41-3 127-82-2 128-03-0 128-04-1
 128-37-0, biological studies 128-80-3 129-06-6 129-67-9 131-11-3
 131-52-2 131-55-5 131-57-7 131-89-5 132-27-4 132-66-1 132-67-2
 133-06-2 133-07-3 133-90-4 136-24-3 136-32-3 136-45-8 136-53-8
 136-77-6 137-16-6 137-26-8 137-30-4 137-40-6 137-41-7 137-42-8
 138-86-3 139-02-6 139-07-1 139-08-2 139-12-8 139-13-9 139-33-3
 139-40-2 139-89-9 140-39-6 140-41-0 140-88-5 141-00-4 141-27-5
 141-66-2 142-03-0 142-47-2 142-59-6 142-71-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(methods and compns. for increasing efficacy of biol. active
 ingredients such as antitumor agents)

IT 142-87-0 143-18-0 143-28-2 143-33-9, Sodium cyanide (Na(CN))
 143-50-0 144-21-8 144-41-2 144-55-8, Carbonic acid monosodium salt,
 biological studies 144-62-7, Ethanedioic acid, biological studies
 145-73-3 145-73-3D, di-(N,N-dimethylcocoamine) salts 145-73-3D, mono-
 and di-(N,N-diethylalkylamine) and mono- and di-(N,N-dimethylalkylamine)
 salts 147-14-8 147-94-4 148-61-8 148-79-8 148-82-3 149-30-4,
 2(3H)-Benzothiazolethione 149-57-5 150-38-9 150-39-0 150-50-5
 150-68-5 150-84-5 151-21-3, biological studies 151-38-2 151-41-7D,
 salts 151-50-8, Potassium cyanide (K(CN)) 151-56-4D, Aziridine,
 derivs. 154-21-2 154-42-7 154-93-8 155-04-4 180-84-7,
 1,7-Dioxaspiro[5.5]undecane 262-12-4D, Dibenzob[e][1,4]dioxin, chloro
 derivs. 288-88-0, 1H-1,2,4-Triazole 289-95-2D, Pyrimidine, analogs
 290-87-9, 1,3,5-Triazine 297-97-2 298-00-0 298-01-1 298-02-2
 298-03-3 298-04-4 298-06-6 298-14-6 299-84-3 300-76-5 301-04-2
 301-12-2 302-01-2, Hydrazine, biological studies 305-03-3 309-00-2
 311-45-5 314-40-9 314-42-1 315-18-4 317-83-9 319-84-6 319-85-7
 327-98-0 328-04-1 329-21-5 330-54-1 330-55-2 330-64-3 333-20-0

333-40-4 333-41-5 333-43-7 334-48-5, Decanoic acid 338-45-4
 352-93-2 379-52-2 404-86-4 443-48-1 465-73-6 470-90-6 471-34-1
 , Carbonic acid calcium salt (1:1), biological studies 475-26-3
 485-31-4 497-19-8, Carbonic acid disodium salt, biological studies
 499-75-2 500-28-7 502-39-6 506-87-6 507-60-8 509-34-2 512-42-5
 513-77-9 513-78-0 513-92-8 515-42-4 515-83-3 517-16-8 518-47-8
 525-79-1 526-18-1 527-07-1 527-09-3 533-96-0 534-16-7 534-52-1
 540-72-7 540-73-8 541-31-1 542-75-6 544-60-5 546-93-0 548-62-9
 554-13-2 555-37-3 556-61-6 557-05-1 557-41-5 563-12-2 563-47-3
 563-63-3 569-64-2 571-58-4 572-48-5 578-94-9 580-48-3 584-08-7
 584-79-2 588-66-9 590-28-3 592-01-8, Calcium cyanide (Ca(CN)2)
 593-29-3 594-30-9 595-33-5 598-02-7 603-33-8
 607-12-5 608-73-1 624-83-9 628-63-7 629-25-4 630-56-8 634-66-2
 637-03-6 637-12-7 639-58-7 640-15-3 643-79-8, 1,2-
 Benzenedicarboxaldehyde 644-64-4 645-05-6 645-92-1 671-04-5
 671-16-9 672-04-8 673-04-1 682-80-4 683-18-1 709-98-8 732-11-6
 741-58-2 756-09-2 759-94-4 786-19-6 811-97-2 813-78-5 814-49-3
 814-91-5 824-39-5 824-78-2 831-76-5 834-12-8 841-06-5 845-52-3
 860-22-0 865-21-4, Vincalcaleukoblastine 867-27-6 872-50-4, biological
 studies 886-50-0 900-95-8 919-44-8 919-54-0 919-76-6 919-86-8
 944-22-9 947-02-4 950-10-7 950-35-6 950-37-8 953-17-3 957-51-7
 959-98-8 960-25-8 961-11-5 961-22-8 962-58-3 963-22-4 973-21-7
 991-42-4 999-81-5 1007-28-9 1011-73-0 1014-69-3 1014-70-6
 1024-57-3 1031-07-8 1066-30-4 1066-33-7 1066-45-1 1067-29-4
 1071-83-6 1076-46-6 1079-33-0 1111-67-7 1111-78-0 1113-02-6
 1113-38-8 1114-71-2 1129-41-5 1134-23-2 1136-84-1 1172-63-0
 1184-57-2 1184-64-1 1186-49-8 1191-17-9 1191-50-0 1191-80-6
 1193-18-6 1194-65-6 1300-34-1 1300-71-6 1300-72-7 1300-78-3
 1301-96-8, Silver oxide (AgO) 1302-42-7 1303-28-2, Arsenic oxide
 (As2O5) 1303-33-9, Arsenic sulfide (As2S3) 1303-86-2, Boron oxide
 (B2O3), biological studies 1303-96-4, Borax (B4Na2O7.10H2O)
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods and compns. for increasing efficacy of biol. active
 ingredients such as antitumor agents)
 IT 1305-62-0, Calcium hydroxide (Ca(OH)2), biological studies 1306-19-0,
 Cadmium oxide (CdO), biological studies 1306-23-6, Cadmium sulfide
 (CdS), biological studies 1308-38-9, Chromium oxide (Cr2O3), biological
 studies 1309-37-1, Iron oxide (Fe2O3), biological studies 1309-48-4,
 Magnesium oxide (MgO), biological studies 1310-58-3, Potassium hydroxide
 (K(OH)), biological studies 1310-65-2, Lithium hydroxide (Li(OH))
 1310-73-2, Sodium hydroxide (Na(OH)), biological studies 1312-76-1
 1313-60-6, Sodium peroxide (Na2O2) 1313-82-2, Sodium sulfide (Na2S),
 biological studies 1314-13-2, Zinc oxide (ZnO), biological studies
 1314-23-4, Zirconium oxide (ZrO2), biological studies 1314-80-3,
 Phosphorus sulfide (P2S5) 1314-84-7, Zinc phosphide (Zn3P2) 1317-36-8,
 Lead oxide (PbO), biological studies 1317-38-0, Copper oxide (CuO),
 biological studies 1317-39-1, Copper oxide (Cu2O), biological studies
 1318-00-9, Vermiculite (Mg0.33[Mg2-3(Al0-1Fe0-1)0-1](Si2.33-3.33Al0.67-
 1.67)(OH)20.4H2O) 1319-53-5, Malachite (Cu2(CO3)(OH)2) 1319-77-3
 1320-67-8 1320-79-2 1322-98-1 1323-19-9 1327-31-7, Lead arsenate
 hydroxide (Pb5(AsO4)3(OH)) 1327-43-1 1327-44-2 1327-53-3, Arsenic
 oxide (As2O3) 1328-53-6, C.I. Pigment Green 7 1330-16-1 1330-20-7,
 biological studies 1330-43-4, Boron sodium oxide (B4Na2O7) 1330-85-4
 1332-40-7 1332-65-6, Copper chloride hydroxide (Cu2Cl(OH)3) 1332-77-0,
 Boron potassium oxide (B4K2O7) 1333-08-0 1333-16-0 1333-22-8, Copper
 hydroxide sulfate (Cu4(OH)6(SO4)) 1333-83-1, Sodium fluoride (Na(FH2))
 1334-75-4 1334-77-6 1335-30-4 1336-15-8, Calcium copper chloride
 oxide 1336-21-6, Ammonium hydroxide ((NH4)(OH)) 1340-69-8, Quaternium
 18-bentonite 1343-88-0 1343-98-2, Silicic acid 1344-00-9

1344-08-7, Sodium sulfide (Na2(Sx))	1344-09-8	1344-28-1, Aluminum oxide (Al2O3), biological studies	1344-43-0, Manganese oxide (MnO), biological studies	1344-67-8, Copper chloride	1344-72-5	1344-73-6
1344-74-7	1344-81-6, Calcium sulfide (Ca(Sx))	1398-61-4, Chitin	1405-89-6, Bacitracin zinc	1420-07-1	1444-64-0	1454-85-9,
1-Heptadecanol	1461-22-9	1490-04-6	1491-41-4	1563-66-2	1570-64-5	
1582-09-8	1594-56-5	1600-27-7	1610-17-9	1610-18-0	1634-78-2	
1646-87-3	1646-88-4	1689-83-4	1689-84-5	1689-99-2	1701-93-5	
1702-17-6	1746-01-6	1746-81-2	1754-58-1	1757-18-2	1762-95-4	
1771-07-9	1776-83-6	1861-32-1	1861-40-1	1891-95-8		
1897-45-6	1910-42-5	1912-24-9	1912-24-9D, dealkylated	1912-25-0		
1912-26-1	1918-00-9	1918-02-1	1918-02-1D, alkanolamine salt			
1918-08-7	1918-11-2	1918-13-4	1918-16-7	1918-18-9	1928-43-4	
1928-45-6	1928-47-8	1928-48-9	1928-57-0	1928-58-1	1929-73-3	
1929-77-7	1929-88-0	1934-21-0	1940-43-8	1954-81-0	1966-58-1	
1967-16-4	1982-47-4	1982-49-6	1982-69-0	1983-10-4	1984-06-1	
2008-39-1	2008-41-5	2008-46-0	2016-48-0	2032-59-9	2032-65-7	
2050-99-9	2074-50-2	2082-79-3	2104-64-5	2104-96-3	2122-70-5	
2155-70-6	2163-68-0	2163-69-1	2163-79-3	2163-80-6	2164-07-0	
2164-08-1	2164-17-2	2173-56-0	2179-25-1	2212-54-6	2212-63-7	
2212-67-1	2227-17-0	2235-25-8	2235-54-3	2244-21-5	2275-06-1	
2275-14-1	2275-18-5	2275-23-2	2279-64-3	2280-44-6D,		
D-Glucopyranose, oligomeric, decyl	octyl glycosides	2282-34-0				
2300-66-5	2302-17-2	2303-17-5	2307-49-5	2310-17-0	2312-76-7	
2321-53-1	2327-02-8	2353-45-9	2385-85-5	2402-95-1	2425-06-1	
2425-10-7	2425-25-4	2425-66-3	2425-85-6	2439-00-1	2439-99-8	
2440-22-4	2463-84-5	2465-65-8	2487-01-6	2492-26-4	2497-06-5	
2497-07-6	2532-49-2	2536-26-7	2536-27-8	2540-82-1	2544-94-7	
2545-59-7	2545-60-0	2577-72-2	2587-90-8	2588-03-6	2588-04-7	
2588-05-8	2588-06-9	2591-21-1	2593-10-4	2593-15-9	2595-54-2	
2597-03-7	2597-92-4	2597-93-5	2597-95-7	2597-97-9	2600-69-3	
2610-86-8	2624-17-1	2631-37-0	2631-40-5	2635-10-1	2636-26-2	
2637-34-5, 2(1H)-Pyridinethione	2642-71-9	2650-18-2	2655-14-3			
2655-15-4	2655-19-8	2665-30-7	2668-92-0	2669-32-1	2674-91-1	
2675-77-6	2682-20-4	2686-99-9	2689-43-2	2699-79-8, Sulfuryl fluoride		
	2701-86-2	2703-13-1	2759-71-9	2764-72-9	2778-04-3	
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)						
(methods and comps. for increasing efficacy of biol. active ingredients such as antitumor agents)						
IT	68921-42-6	68957-70-0	69126-94-9D, derivs.	69254-40-6	69280-13-3,	
Hostaphat MDAR-N	040	69309-47-3	69312-67-0	69335-91-7	69409-94-5	
69462-12-0	69484-12-4	69484-13-5	69484-14-6	69516-34-3		
69581-33-5	69632-93-5	69632-97-9	69632-98-0	69633-04-1		
69653-69-6	69770-45-2	69806-34-4	69806-40-2	69806-50-4		
69820-27-5	70024-53-2	70124-77-5	70193-21-4	70217-36-6		
70393-85-0	70630-17-0	71283-80-2	71317-73-2	71526-07-3		
71561-11-0	71626-11-4	71697-59-1	71751-41-2, Avermectin B1			
72146-51-1, Morwet IP	72178-02-0	72269-48-8	72348-92-6	72459-58-6		
72490-01-8	72598-35-7	72850-64-7	72915-82-3	72963-72-5		
73250-68-7	73394-27-1	73468-21-0, Atplus 300F	73519-50-3			
73886-28-9	73989-17-0, Avermectin	74051-80-2	74070-46-5	74222-97-2		
74223-56-6	74223-64-6	74712-19-9	74738-17-3	74782-23-3		
75497-92-6	75736-33-3	75747-77-2	76120-02-0	76397-81-4		
76416-93-8, Tenneco	500-100	76578-12-6	76578-14-8	76608-88-3		
76674-21-0	76738-62-0	76930-44-4, Po-san A	77182-82-2	77207-01-3		
77227-69-1	77501-60-1	77501-63-4	77503-28-7	77503-29-8		
77732-09-3	78110-38-0	78327-32-9	78357-48-9	78370-21-5		
78403-23-3	78863-62-4	79241-46-6	79277-27-3	79277-67-1		
79510-48-8	79538-32-2	79540-50-4	79622-59-6	79910-32-0		

79983-71-4 80060-09-9 80625-77-0 81334-34-1 81335-37-7
 81335-46-8 81335-47-9 81335-77-5 81412-43-3, Tridemorph 81510-83-0
 81591-81-3 82010-74-0 82010-75-1 82010-77-3 82010-79-5
 82010-82-0 82010-83-1 82027-59-6 82097-50-5 82211-24-3
 82558-50-7 82560-54-1 82633-79-2 82657-04-3 82692-44-2
 82810-23-9D, alkyl ethers 83055-99-6 83121-18-0 83130-01-2
 83164-33-4 83318-76-7 83542-69-2 83542-80-7 83542-83-0
 83601-83-6 83657-22-1 83657-24-3 83733-82-8 83869-01-6, TF 310
 83982-06-3D, N-alkyl, sodium salt, complex with iodine 84082-88-2
 84082-93-9 84332-86-5 84478-52-4 84496-56-0 85411-41-2, T-Mulz AO
 2 85509-19-9 85785-20-2 86209-51-0 86479-06-3 86598-92-7
 86763-47-5 86848-85-3 87130-20-9 87237-48-7 87310-56-3
 87392-12-9 87547-04-4 87674-68-8 87757-18-4 87820-88-0
 87917-06-4, Tensiofix B 7416 87917-07-5, Tensiofix B 7453 88211-73-8
 88349-88-6 88485-37-4 88671-89-0 88678-67-5 88859-94-3
 89269-64-7 89415-87-2 89784-60-1 90035-08-8 90338-20-8
 90982-32-4 91125-43-8 91315-15-0, Aldimorph 91465-08-6 92170-50-8
 92302-40-4 92529-51-6, Sure-Sol 180 93697-74-6 94050-52-9
 94051-08-8 94125-34-5 94189-31-8, Stepanant A 94361-06-5
 94593-91-6 95465-99-9 95480-33-4 95507-03-2 95977-29-0
 96182-53-5 96491-05-3 96525-23-4 96949-21-2, Rhamsan gum
 97780-06-8 98389-04-9 98730-04-2 98886-44-3 99105-77-8
 99129-21-2 99283-00-8 99283-01-9 99485-76-4 99607-70-2
 99662-11-0 100646-51-3 100728-84-5 101007-06-1 101200-48-0
 101205-02-1 101362-24-7 101463-69-8 101917-66-2 102767-64-6
 102851-06-9 103055-07-8 103112-36-3 103737-35-5, T-Mulz VO
 104030-54-8 104040-78-0 104040-79-1 104078-12-8 104098-48-8
 105512-06-9 105864-15-1, Morwet EFW 106040-48-6 106700-29-2
 107534-96-3 108189-58-8 108731-70-0 110956-75-7 111353-84-5
 111479-05-1 111578-32-6 111872-58-3 111988-49-9 111991-09-4
 112226-61-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods and compns. for increasing efficacy of biol. active
 ingredients such as antitumor agents)

IT 99-26-3 594-30-9 603-33-8 1776-83-6
 88349-88-6 99607-70-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods and compns. for increasing efficacy of biol. active
 ingredients such as antitumor agents)

RN 99-26-3 CAPLUS

CN 1,3,2-Benzodioxabismole-5-carboxylic acid, 2,7-dihydroxy- (CA INDEX NAME)



RN 594-30-9 CAPLUS

CN Bismuth, dichlorotriphenyl- (CA INDEX NAME)




RN 603-33-8 CAPLUS

CN Bismuthine, triphenyl- (CA INDEX NAME)




RN 1776-83-6 CAPLUS

CN Phosphonothioic acid, P-phenyl-, O-ethyl O-(8-quinoliny) ester (CA INDEX NAME)




RN 88349-88-6 CAPLUS

CN Acetic acid, 2-[(5-chloro-8-quinoliny)oxy]- (CA INDEX NAME)



RN 99607-70-2 CAPLUS

CN Acetic acid, 2-[(5-chloro-8-quinoliny)oxy]-, 1-methylhexyl ester (CA INDEX NAME)



L60 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:944307 CAPLUS Full-text

DOCUMENT NUMBER: 142:316861

TITLE: Ir-catalyzed enantioselective hydrogenation of substituted aromatic pyridine and pyrazine rings
 INVENTOR(S): Zhou, Yonggui; Lu, Shengmei; Yang, Pengyu; Wang, Wenbo
 PATENT ASSIGNEE(S): Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Peop. Rep. China

SOURCE: Faming Zhuanli Shengqing Gongkai Shuomingshu, 9 pp.
 CODEN: CNXKEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1468852	A	20040121	CN 2003-138283	20030530
PRIORITY APPLN. INFO.:			CN 2003-138283	20030530

OTHER SOURCE(S): CASREACT 142:316861

AB Enantioselective hydrogenation of substituted/fused aromatic pyridine and pyrazine compds. was realized in a solvent in the presence of a iridium catalyst system at 0-80°C under 1-100 atmospheric. The catalyst system is composed of iridium catalyst, additive and P/N/O/S-containing chiral ligand. The invented process features mild reaction condition (e.g., rt, normal pressure) and high e.e. (generally >90%), and can be used to synthesize some important compds., such as angustreine. For instance, 2-methylquinoline was hydrogenated under 30-50 atm in the presence of [Ir(CO)2Cl]2, iodine and (R)-2,2'-Bis(diphenylphosphino)-6,6'-dimethoxy-1,1'-diphenyl to give (R)-2-methyl-1,2,3,4-tetrahydroquinoline with 94% yield and 94% e.e.

IC ICM C07D215-02

ICS C07D241-42; C07B035-00; B01J031-16

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 27

IT 91-63-4 109-65-9 612-96-4 877-43-0 1078-28-0

1128-61-6 1613-32-7 1613-34-9 1613-41-8

7251-61-8 7661-39-4 20849-53-0 29526-24-7

93005-16-4 95279-34-8 102594-19-4 124902-95-0 132148-33-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(Ir-catalyzed enantioselective hydrogenation of substituted aromatic pyridine and pyrazine rings)

IT 88-96-0, Phthalamide 311-28-4, Tetrabutylammonium iodide 624-73-7,

19-2-Diiodoethane 1493-13-6, Triflic acid 1643-19-2, Tetrabutylammonium

bromide 7553-56-2, Iodine, uses 7664-93-9, Sulfuric acid, uses

7787-64-6, BiI3 10034-85-2, Hydriodic acid 10035-10-6,

Hydrobromic acid, uses 16872-11-0, Fluoroboric acid

RL: CAT (Catalyst use); USES (Uses)

(additive; Ir-catalyzed enantioselective hydrogenation of substituted aromatic pyridine and pyrazine rings)

IT 91-63-4 877-43-0 1128-61-6 1613-32-7

1613-34-9 7661-39-4 20849-53-0


93005-16-4

RL: RCT (Reactant); RACT (Reactant or reagent)


(Ir-catalyzed enantioselective hydrogenation of substituted aromatic pyridine and pyrazine rings)

RN 91-63-4 CAPLUS


CN Quinoline, 2-methyl- (CA INDEX NAME)




RN 877-43-0 CAPLUS
 CN Quinoline, 2,6-dimethyl- (CA INDEX NAME)




RN 1128-61-6 CAPLUS
 CN Quinoline, 6-fluoro-2-methyl- (CA INDEX NAME)




RN 1613-32-7 CAPLUS
 CN Quinoline, 2-propyl- (CA INDEX NAME)




RN 1613-34-9 CAPLUS
 CN Quinoline, 2-ethyl- (CA INDEX NAME)




RN 7661-39-4 CAPLUS
 CN Quinoline, 2-butyl- (CA INDEX NAME)



RN 20849-53-0 CAPLUS
 CN Quinoline, 2-(3-butenyl)- (8CI, 9CI) (CA INDEX NAME)



RN 93005-16-4 CAPLUS
CN Quinoline, 2-pentyl- (CA INDEX NAME)



IT 7787-64-6, BiI3
RL: CAT (Catalyst use); USES (Uses)
(additive; Ir-catalyzed enantioselective hydrogenation of substituted
aromatic pyridine and pyrazine rings)
RN 7787-64-6 CAPLUS
CN Bismuthine, triiodo- (CA INDEX NAME)



L60 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:305177 CAPLUS Full-text
DOCUMENT NUMBER: 140:304723
TITLE: Polyurethane composition containing a bismuth catalyst
INVENTOR(S): Burckhardt, Urs; Diener, Andreas
PATENT ASSIGNEE(S): Sika Technology A.-G., Switz.
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1408062	A1	20040414	EP 2002-22561	20021008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2501224	A1	20040422	CA 2003-2501224	20031001
WO 2004033519	A1	20040422	WO 2003-EP10931	20031001
WO 2004033519	A9	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


AU 2003285287 A1 20040504 AU 2003-285287 20031001
 EP 1551895 A1 20050713 EP 2003-778270 20031001

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003015173 A 20050823 BR 2003-15173 20031001
 CN 1703437 A 20051130 CN 2003-80101128 20031001
 CN 100354331 C 20071212
 JP 2006502267 T 20060119 JP 2004-542408 20031001
 US 20060180274 A1 20060817 US 2005-529894 20050322
 MX 2005PA03678 A 20050816 MX 2005-PA3678 20050407

PRIORITY APPLN. INFO.: EP 2002-22561 A 20021008
 WO 2003-EP10931 W 20031001

OTHER SOURCE(S): MARPAT 140:304723
 GI




AB One-component polyurethane compns., containing isocyanate-terminated polyurethane prepolymers and combinations of Bi-derivs. with N-containing heterocycles I or II (R1 - R6 = H, Me, Et, Pr, iso-Pr, Bu, iso-Bu, tert-Bu, C5-12 alkyl, COOH, COOR' or halogen, R7 = H, Me, Et, C3-12 alkyl, OH, OR'', R8 = alkylene- or alkyleneether group, R' = alkyl, R'' = alkyl or alkyl, containing heteroatom) as a catalysts are useful as long-term stable adhesives, sealants, clear coatings, especially as automobile coatings. Polyurethane moisture-curable adhesive paste, based on NCO-terminated prepolymer with NCO-content 2.12 weight% (manufacturing by reacting 2155 g of polyol (Acclaim 4200N) and 4310 g of polyol (Caradol MD34-02) with 1035 g of MDI (Desmodur 44MC L) at 80°) and combination of tri(neodecanoate) Bi with 8-hydroxyquinoline as catalyst exhibits an excellent adhesion to steel sheet and could be applied together with a Sn-based catalyst.

IC ICM C08G018-12
 ICS C08G018-30; C08G018-22; C09D175-04; C09J175-04; B01J031-18

CC 37-6 (Plastics Manufacture and Processing)

IT Polyurethanes, preparation
 RL: IMF (Industrial manufacture); POF (Polymer in formulation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (polyoxyalkylene-; one-component polyurethane compns., containing

- Bi-combinations with N-containing heterocycles as catalysts for adhesives, sealants and clear coatings)
- IT 34364-26-6, Bismuth trineodecanoate
 RL: CAT (Catalyst use); USES (Uses)
 (NeoBi 200; one-component polyurethane compns., containing Bi-combinations with N-containing heterocycles as catalysts for adhesives, sealants and clear coatings)
- IT 67-51-6, 3,5-Dimethylpyrazole 91-22-5, Quinoline, uses
 91-63-4, 2-Methylquinoline 148-24-3, 8-Hydroxyquinoline, uses 288-32-4, Imidazol, uses 366-18-7, 2,2'-Bipyridyl 586-98-1, 2-Hydroxymethylpyridine 614-97-1, 5-MethylBenzImidazole 4083-64-1D, Toluene-4-sulfonyl isocyanate, reaction product with bismuth trineodecanoate and diisodecylphthalate 57310-75-5
 RL: CAT (Catalyst use); USES (Uses)
 (co-catalyst; one-component polyurethane compns., containing Bi-combinations with N-containing heterocycles as catalysts for adhesives, sealants and clear coatings)
- IT 34364-26-6, Bismuth trineodecanoate
 RL: CAT (Catalyst use); USES (Uses)
 (NeoBi 200; one-component polyurethane compns., containing Bi-combinations with N-containing heterocycles as catalysts for adhesives, sealants and clear coatings)
- RN 34364-26-6 CAPLUS
- CN Neodecanoic acid, bismuth(3+) salt (3:1) (CA INDEX NAME)




● 1/3 Bi(III)

- IT 91-22-5, Quinoline, uses 91-63-4, 2-Methylquinoline
 148-24-3, 8-Hydroxyquinoline, uses 57310-75-5
 RL: CAT (Catalyst use); USES (Uses)
 (co-catalyst; one-component polyurethane compns., containing Bi-combinations with N-containing heterocycles as catalysts for adhesives, sealants and clear coatings)
- RN 91-22-5 CAPLUS
- CN Quinoline (CA INDEX NAME)



- RN 91-63-4 CAPLUS
- CN Quinoline, 2-methyl- (CA INDEX NAME)




RN 148-24-3 CAPLUS
 CN 8-Quinolinol (CA INDEX NAME)




RN 57310-75-5 CAPLUS
 CN Quinoline, 8,8'-[oxybis(2,1-ethanediylloxy-2,1-ethanediylloxy)]bis- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:696215 CAPLUS Full-text
 DOCUMENT NUMBER: 139:215875
 TITLE: Cathodic electrodeposition coating (CED) agents containing bismuth complexes, preparation, and use
 INVENTOR(S): Hermann, Ulrich; Kuehhirt, Walter; Schipfer, Rudolf
 PATENT ASSIGNEE(S): E. I. Du Pont de Nemours and Company, Germany
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030164299	A1	20030904	US 2002-90654	20020304
US 6811667	B2	20041102		
EP 1342757	A1	20030910	EP 2003-2772	20030207
EP 1342757	B1	20051026		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 ES 2250756 T3 20060416 ES 2003-2772 20030207
 JP 2003301126 A 20031021 JP 2003-57642 20030304
 PRIORITY APPLN. INFO.: US 2002-90654 A 20020304
 AB Waterborne CED coating agents contain resin solids and optionally pigments, fillers and/or conventional coating additives, and ≥ 1 Bi complex with ligands selected from hydroxyquinolines, 1,2-dioximes, 1,3-dioximes, and N,N'-diarylthiocarbazides and combinations (0.1-2.5%). A mixture of 111 g bismuth oxide, 208 g 8-hydroxyquinoline, and 50 g N-methylpyrrolidone was boiled under reflux for 30 min to give an example complex.
 IC ICM B05D003-00
 ICS C25D015-00
 INCL 204499000; 204510000
 CC 42-3 (Coatings, Inks, and Related Products)
 Section cross-reference(s): 78
 IT 95-45-4DP, Diacetyl Dioxime, bismuth complex 148-24-3DP, 8-Hydroxyquinoline, bismuth complex 622-03-7DP, bismuth complex 7440-69-9DP, Bismuth, complex
 RL: CAT (Catalyst use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
 (bismuth complexes for cathodic electrodeposition coatings not effected by phosphate contamination)
 IT 148-24-3DP, 8-Hydroxyquinoline, bismuth complex 7440-69-9DP, Bismuth, complex
 RL: CAT (Catalyst use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
 (bismuth complexes for cathodic electrodeposition coatings not effected by phosphate contamination)
 RN 148-24-3 CAPLUS
 CN 8-Quinolinel (CA INDEX NAME)



RN 7440-69-9 CAPLUS
CN Bismuth (CA INDEX NAME)

Bi

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 2003:376338 CAPLUS Full-text
DOCUMENT NUMBER: 138:347624
TITLE: Method for laser patterning a multilayered conductor/substrate structure
INVENTOR(S): Kian, Kouroche; Heydarpour, Ramin
PATENT ASSIGNEE(S): Avery Dennison Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030092267	A1	20030515	US 2001-8808	20011113
US 6602790	B2	20030805		

PRIORITY APPLN. INFO.: US 2001-8808 20011113

AB The invention relates to a method for laser patterning a multilayered conductor/substrate structure for use in image display devices. The method consists of steps of (i) providing a multilayered conductor/substrate structure which includes a plastic substrate and at least one conductive layer overlying the plastic substrate; and (ii) irradiating the multilayered conductor/substrate structure with UV radiation such that portions of the conductive layer are ablated from the surface to pattern the multilayered conductor/substrate structure.

IC ICM H01L021-302
ICS H01L021-26

INCL 438690000; 438706000; 438707000; 438795000

CC 76-14 (Electric Phenomena)
Section cross-reference(s): 38, 73, 78

IT Polyurethanes, uses
RL: TEM (Technical or engineered material use); USES (Uses)
(aliphatic, substrate; method for laser patterning a multilayered conductor/substrate structure)

IT 1312-43-2, Indium oxide 7440-03-1, Niobium, uses 7440-21-3, Silicon, uses 7440-22-4, Silver, uses 7440-25-7, Tantalum, uses 7440-32-6, Titanium, uses 7440-45-1, Cerium, uses 7440-47-3, Chromium, uses 7440-56-4, Germanium, uses 7440-57-5, Gold, uses 7440-58-6, Hafnium, uses 7440-67-7, Zirconium, uses 7440-69-9, Bismuth, uses 11129-18-3, Cerium oxide 50926-11-9, Indium tin oxide
RL: TEM (Technical or engineered material use); USES (Uses)
(conductor; method for laser patterning a multilayered conductor/substrate structure)

IT 91-22-5D, Quinoline, salts 123-54-6D, Acetylacetone, metal complexes 148-24-3D, 8-Hydroxyquinoline, salts 7440-31-5D, Tin, metal complexes 13598-36-2D, Phosphonic acid, bisphosphonate metal complexes 17056-99-4D, 5-Hydroxyquinoxaline, metal complexes

41999-83-1D, Maleonitriledithiol, metal complexes
 RL: TEM (Technical or engineered material use); USES (Uses)
 (luminescent material; method for laser patterning a multilayered
 conductor/substrate structure)
 IT 7440-69-9, Bismuth, uses
 RL: TEM (Technical or engineered material use); USES (Uses)
 (conductor; method for laser patterning a multilayered
 conductor/substrate structure)
 RN 7440-69-9 CAPLUS
 CN Bismuth (CA INDEX NAME)

Bi

IT 91-22-5D, Quinoline, salts 148-24-3D,
 8-Hydroxyquinoline, salts
 RL: TEM (Technical or engineered material use); USES (Uses)
 (luminescent material; method for laser patterning a multilayered
 conductor/substrate structure)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)



RN 148-24-3 CAPLUS
 CN 8-Quinolinol (CA INDEX NAME)



L60 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:539631 CAPLUS Full-text
 DOCUMENT NUMBER: 137:95531
 TITLE: Reaction method utilizing diaphragm type catalyst and
 apparatus therefor
 INVENTOR(S): Mizukami, Fujio; Niwa, Shuichi; Toba, Makoto; Itoh,
 Naotsugu; Saito, Tomonari; Nanba, Takemi; Shoji,
 Hiroshi; Haba, Kazuhiko
 PATENT ASSIGNEE(S): National Institute of Advanced Industrial Science and
 Technology, Japan; NOK Corporation
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055465	A1	20020718	WO 2001-JP11542	20011227
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2002205968	A	20020723	JP 2001-403	20010105
JP 2002284727	A	20021003	JP 2001-88282	20010326
CA 2434162	A1	20020718	CA 2001-2434162	20011227
AU 2002216419	A1	20020724	AU 2002-216419	20011227
EP 1357103	A1	20031029	EP 2001-273197	20011227
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20040110995	A1	20040610	US 2003-451624	20031210
US 6911563	B2	20050628		
PRIORITY APPLN. INFO.:			JP 2001-403	A 20010105
			JP 2001-88282	A 20010326
			WO 2001-JP11542	W 20011227

OTHER SOURCE(S): MARPAT 137:95531

AB This document discloses a method for carrying out a reaction of one substance capable of being activated by a catalyst with another substance capable of reacting with said substance activated, characterized in that the substance capable of being activated is activated by passing the substance through a diaphragm type catalyst and the reaction is thus performed in one step; a method for producing an aromatic alc. utilizing the above method; and a reaction apparatus suitable for these reactions. In the method, one substance is activated by passing through a diaphragm type catalyst and an objective reaction is carried out by using the activated substance, and the reaction can be performed safely in one step. Moreover, the contact of the above activated substance with a compound to be reacted therewith can be freely controlled, and therefore, overreaction can be prevented and a target product can be produced in high yield. The method is thus markedly advantageous from an economical view point as a com. process for producing oxygen-containing organic compds. such as an aromatic alc., a ketone, an aldehyde, a carboxylic acid and an epoxide. Thus, oxidation of propylene by the title method gave acrolein with 70 mol% conversion of propylene.

IC ICM C07C045-34
 ICS C07C045-35; C07C047-22; C07C049-08; C07C049-403; C07C029-50; C07C035-08; C07C037-58; C07C039-04; C07C039-07; C07C039-14; C07B061-00; B01J019-24; C07D301-08; C07D301-10; C07D303-04; C07D213-63; C07D309-32; C07D307-58; C07D333-32

CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)
 Section cross-reference(s): 21, 67

IT 7439-89-6, Iron, uses 7439-91-0, Lanthanum, uses 7439-96-5, Manganese, uses 7439-98-7, Molybdenum, uses 7440-02-0, Nickel, uses 7440-03-1, Niobium, uses 7440-04-2, Osmium, uses 7440-05-3, Palladium, uses 7440-06-4, Platinum, uses 7440-18-8, Ruthenium, uses 7440-19-9, Samarium, uses 7440-22-4, Silver, uses 7440-25-7, Tantalum, uses 7440-32-6, Titanium, uses 7440-33-7, Tungsten, uses 7440-45-1, Cerium, uses 7440-47-3, Chromium, uses 7440-48-4, Cobalt, uses 7440-57-5, Gold, uses 7440-62-2, Vanadium, uses 7440-65-5, Yttrium, uses 7440-68-9, Bismuth, uses 12735-99-8 56404-84-3
 RL: CAT (Catalyst use); USES (Uses)

(reaction method utilizing diaphragm type catalyst and apparatus therefor)

IT 71-43-2, Benzene, reactions 85-01-8, Phenanthrene, reactions 86-73-7, Fluorene 91-20-3, Naphthalene, reactions 91-22-5, Quinoline, reactions 92-52-4, Biphenyl, reactions 108-88-3, Toluene, reactions 109-97-7, Pyrrole 110-00-9, Furan 110-02-1, Thiophene 110-83-8, Cyclohexene, reactions 110-86-1, Pyridine, reactions 115-07-1, Propylene, reactions 119-64-2 120-12-7, Anthracene, reactions 120-72-9, Indole, reactions 120-73-0, Purine 253-82-7, Quinazoline 275-51-4, Azulene 289-66-7, Pyran 290-37-9, Pyrazine 496-11-7, Indane 694-59-7, Pyridine oxide 827-52-1, Cyclohexylbenzene 1321-94-4, Methylanththalene 1333-74-0, Hydrogen, reactions 7782-44-7, Oxygen, reactions 10028-15-6, Ozone, reactions 12678-01-2, Phenanthroline 37275-48-2, Bipyridine 87664-16-2, Terpyridine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction method utilizing diaphragm type catalyst and apparatus therefor)

IT 7440-69-9, Bismuth, uses

RL: CAT (Catalyst use); USES (Uses)

(reaction method utilizing diaphragm type catalyst and apparatus therefor)

RN 7440-69-9 CAPLUS

CN Bismuth (CA INDEX NAME)

Bi

IT 91-22-5, Quinoline, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction method utilizing diaphragm type catalyst and apparatus therefor)

RN 91-22-5 CAPLUS

CN Quinoline (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:146311 CAPLUS Full-text

DOCUMENT NUMBER: 134:326116

TITLE: BiO/O₂ as a new catalytic system for the oxidation of α -ketols, α -hydroxy acids and epoxides

AUTHOR(S): Coin, Christine; Le Boisselier, Veronique; Favier, Isabelle; Postel, Michele; Dunach, Elisabeth

CORPORATE SOURCE: Laboratoire de Chimie Moléculaire, Associé au C.N.R.S., Université de Nice-Sophia Antipolis, Nice, 06108, Fr.

SOURCE: European Journal of Organic Chemistry (2001), (4), 735-740

CODEN: EJOCFK; ISSN: 1434-193X


PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:326116

- AB BiO has been used as a catalyst for the oxidative C-C bond cleavage under O₂ of α -ketols, α -hydroxy acids and terminal epoxides, to give the corresponding carboxylic acids. The results are compared to those obtained in similar oxidation reactions catalyzed by BiIII carboxylates. These reactions constitute the first example of the catalytic use of BiO in oxidation reactions, and the first evidence for a BiIII/BiO redox couple under mol. oxygen.
- CC 22-7 (Physical Organic Chemistry)
Section cross-reference(s): 21
- IT 64-19-7, Acetic acid, uses 69-72-7, Salicylic acid, uses 88-99-3, Phthalic acid, uses 93-10-7, 2-Quinolinedicarboxylic acid 96-97-9, Benzoic acid, 2-hydroxy-5-nitro- 186028-05-7, Bismuth(III) phthalate
RL: CAT (Catalyst use); USES (Uses)
(BiO/O₂ as a new catalytic system for the oxidation of α -ketols, α -hydroxy acids and epoxides)
- IT 7440-69-9, Bismuth, reactions
RL: CAT (Catalyst use); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); RCT (Reactant); FORM (Formation, nonpreparative); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(BiO/O₂ as a new catalytic system for the oxidation of α -ketols, α -hydroxy acids and epoxides)
- IT 90-64-2, Mandelic acid 141643-64-3
RL: CAT (Catalyst use); PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(BiO/O₂ as a new catalytic system for the oxidation of α -ketols, α -hydroxy acids and epoxides)
- IT 93-10-7, 2-Quinolinedicarboxylic acid 186028-05-7, Bismuth(III) phthalate
RL: CAT (Catalyst use); USES (Uses)
(BiO/O₂ as a new catalytic system for the oxidation of α -ketols, α -hydroxy acids and epoxides)
- RN 93-10-7 CAPLUS
- CN 2-Quinolinedicarboxylic acid (CA INDEX NAME)



- RN 186028-05-7 CAPLUS
- CN 2,4,3-Benzodioxabismepin-1,5-dione, 3-hydroxy- (CA INDEX NAME)



- IT 7440-69-9, Bismuth, reactions

RL: CAT (Catalyst use); FMU (Formation, unclassified); PEP
 (Physical, engineering or chemical process); RCT (Reactant); FORM
 (Formation, nonpreparative); PROC (Process); RACT (Reactant or reagent);
 USES (Uses)

(BiO/O₂ as a new catalytic system for the oxidation of α -ketols,
 α -hydroxy acids and epoxides)

RN 7440-69-9 CAPLUS

CN Bismuth (CA INDEX NAME)

Bi


IT 141643-64-3

RL: CAT (Catalyst use); PEP (Physical, engineering or chemical
 process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent); USES
 (Uses)

(BiO/O₂ as a new catalytic system for the oxidation of α -ketols,
 α -hydroxy acids and epoxides)

RN 141643-64-3 CAPLUS

CN Bismuth, tetrakis(α -hydroxybenzeneacetato)- μ -oxodi- (9CI) (CA
 INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:824206 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 133:362613

TITLE: Amination process and catalysts for the conversion of
 aromatic hydrocarbons and aromatic heterocycles into
 amines

INVENTOR(S): Poojary, Damodara; Borade, Ramesh; Hagemeyer, Alfred;
 Dube, Christopher E.; Zhou, Ziao Ping; Nothels,
 Ulrich; Armbrust, Ralph; Rasp, Christian; Lowe, David
 M.

PATENT ASSIGNEE(S): Symyx Technologies Inc., USA; Bayer A.G.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069804	A1	20001123	WO 2000-US13266	20000515
<p>W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW</p> <p>RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG</p>				
US 6933409	B1	20050823	US 2000-571567	20000515
PRIORITY APPLN. INFO.:			US 1999-148057P	P 19990513
OTHER SOURCE(S): CASREACT 133:362613; MARPAT 133:362613				
AB	Platinum-group-metal-reducible-metal-oxide catalysts (e.g., Pd/nickel oxide/ceria), effective for the direct amination of aromatic hydrocarbons (e.g., benzene) and heterocyclic compds. (e.g., quinoline) with an aminating agent (e.g., ammonia) into amines (e.g., aniline), are presented. These cataloxidants can be regenerated without substantial loss of performance.			
IC	ICM C07C209-02 ICS C07C211-46			
CC	25-4 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds) Section cross-reference(s): 27, 67			
IT	1304-76-3, Bismuth oxide, uses 1312-81-8, Lanthanum oxide 1313-99-1, Nickel oxide, uses 1332-37-2, Iron oxide, uses 1344-70-3, Copper oxide 7446-07-3, Tellurium oxide 11099-11-9, Vanadium oxide 11104-61-3, Cobalt oxide 11129-18-3, Cerium oxide 11129-60-5, Manganese oxide 12036-32-7, Praseodymium oxide 12036-41-8, Terbium oxide 12624-27-0, Rhenium oxide RL: CAT (Catalyst use); USES (Uses) (amination catalysts for the conversion of aromatic hydrocarbons and aromatic heterocycles into amines)			
IT	57-13-6, Urea, reactions 71-43-2, Benzene, reactions 74-89-5, Methylamine, reactions 91-20-3, Naphthalene, reactions 91-22-5, Quinoline, reactions 108-88-3, Toluene, reactions 108-95-2, Phenol, reactions 110-86-1, Pyridine, reactions 120-12-7, Anthracene, reactions 506-87-6, Ammonium carbonate 1111-78-0, Ammonium carbamate 1330-20-7, Xylene, reactions 7664-41-7, Ammonia, reactions 7803-49-8, Hydroxylamine, reactions RL: RCT (Reactant); RACT (Reactant or reagent) (amination process and catalysts for the conversion of aromatic hydrocarbons and aromatic heterocycles into amines)			
IT	1304-76-3, Bismuth oxide, uses RL: CAT (Catalyst use); USES (Uses) (amination catalysts for the conversion of aromatic hydrocarbons and aromatic heterocycles into amines)			
RN	1304-76-3 CAPLUS			
CN	Bismuth oxide (Bi2O3) (CA INDEX NAME)			
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***				
IT	91-22-5, Quinoline, reactions RL: RCT (Reactant); RACT (Reactant or reagent) (amination process and catalysts for the conversion of aromatic hydrocarbons and aromatic heterocycles into amines)			
RN	91-22-5 CAPLUS			
CN	Quinoline (CA INDEX NAME)			



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:259972 CAPLUS Full-text
 DOCUMENT NUMBER: 132:293042
 TITLE: Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
 INVENTOR(S): Van Lengerich, Bernhard H.
 PATENT ASSIGNEE(S): General Mills, Inc., USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021504	A1	20000420	WO 1999-US20905	19991006
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 7201923	B1	20070410	US 1999-233443	19990120
EP 1900283	A2	20080319	EP 2007-24107	19990323
R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, LT, LV, RO, SI			
CA 2345815	A1	20000420	CA 1999-2345815	19991006
AU 9963872	A	20000501	AU 1999-63872	19991006
AU 777977	B2	20041104		
EP 1119345	A1	20010801	EP 1999-951433	19991006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002527375	T	20020827	JP 2000-575480	19991006
PRIORITY APPLN. INFO.:			US 1998-103700P	P 19981009
			US 1998-109696P	P 19981124
			US 1999-233443	A 19990120
			US 1998-79060P	P 19980323
			EP 1999-912231	A3 19990323
			WO 1999-US20905	W 19991006

AB A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished at a low temperature and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liquid content of the liquid encapsulant component provides substantially all or completely all of the

liquid plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixture or dough. Removal of liquid plasticizer prior to extrusion is not needed to adjust the viscosity of the mixture for formability. Release of an active component from the matrix may be delayed or controlled over time so that the active component is delivered when and where it is needed to perform its intended function. Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant.

IC ICM A61K009-10

CC 17-13 (Food and Feed Chemistry)

Section cross-reference(s): 63

IT Amino acids, biological studies

Castor oil

Cod liver oil

Dipeptides

Enzymes, biological studies

Estrogens

Fats and Glyceridic oils, biological studies

Glucocorticoids

Glutens

Hormones, plant

Lanolin

Mineral elements, biological studies

Paraffin waxes, biological studies

Pentosans

Peptides, biological studies

Phospholipids, biological studies

Polyolefins

Polyurethanes, biological studies

Pumice

Steroids, biological studies

Tetracyclines

Trace elements, biological studies

Tuberculin

Vitamins

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(encapsulation of sensitive liquid components into matrix to obtain discrete shelf-stable particles)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-09-9 50-12-4, Mephenytoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptylin 50-49-7 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate 50-63-5, Chloroquine phosphate 50-78-2, Aspirin 50-81-7, L-Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-52-5, Propyl thiouracil 51-55-8, Atropine, biological studies 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-74-1, Histamine phosphate 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl

hydrochloride 52-53-9, Verapamil 52-67-5, Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1, L-Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1, Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-47-7, Pyridoxal phosphate 54-64-8, Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1, Lithioronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan 56-47-3, Deoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-54-2 56-75-7, Chloramphenicol 56-84-8, L-Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-92-1, biological studies 57-96-5, Sulfinpyrazone 58-00-4, Apomorphine 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone 58-25-3, Clordiazepoxide 58-27-5, Menadione 58-32-2, Dipyrizamide 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride 58-61-7D, Adenosine, derivs. 58-85-5 58-89-9, Lindane 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin, biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7, Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4, L-Tyrosine, biological studies 60-56-0, Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1, Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 61-90-5, L-Leucine, biological studies 62-31-7, Dopamine hydrochloride 62-44-2, Phenacetin 62-67-9, Nalorphine 62-90-8, Nandrolone phenpropionate 63-68-3, Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-72-2, Chlorotetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8, Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotestosterone 67-97-0, Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1, L-Histidine, biological studies 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8, Isopropamide iodide 72-14-0, Sulfathiazole 72-17-3 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 72-33-3, Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan, biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiethylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-57-2, Oxytetracycline 80-08-0 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3,

Dienestrol 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 88-04-0, Chloroxylenol 89-57-6, 5-Aminosalicylic acid 90-33-5, 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripeleminamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 94-24-6, Tetracaine 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzene 103-86-6, Hydroxyamphetamine 103-90-2, 104-28-9, Cinoxate 104-31-4, Benzonatate 106-48-9, 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liquid components into matrix to obtain discrete shelf-stable particles)

IT 115-38-8, Mephobarbital 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0, Benzethonium chloride 121-75-5, Malathion 123-31-9, Hydroquinone, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscaine 129-20-4, Oxyphebutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clioquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxbenzone 132-17-2, Benztropine mesylate 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9, Methyclothiazide 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-77-6, Hexyl resorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital sodium 144-14-9, Anileridine 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-52-4, Nafcillin 147-85-3, L-Proline, biological studies 148-79-8 148-82-3, Mephalan 151-67-7, Halothane 152-62-5, Dydrogesterone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrine 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclozine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, Racepinefrine 343-55-5, Dicloxacillin sodium 345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluclozinide 357-07-3, Oxymorphone hydrochloride 359-83-1D, Pentazocine, salts 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone 388-51-2 389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene 426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2, Phenprocoumon 437-74-1, Xantanol

nicotinate 439-14-5, Diazepam 440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole 446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone 471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin 479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine 511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate 514-65-8, Biperiden 518-47-8, Fluorescein sodium 520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6, 527-07-1, Sodium gluconate 532-03-6, Methocarbamol 533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0, Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol 549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaïne hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2, Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide hydrochloride 555-30-6, Methyldopa 557-34-6, Zinc acetate 562-10-7, 564-25-0, 577-11-7, Docusate sodium 579-56-6, Isoxsuprine hydrochloride 587-61-1, Propylidone 590-63-6, Bethanechol chloride 595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1, Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine 620-61-1, Hycosamine sulfate 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 672-87-7, Metyrosine 709-55-7, Etilfrine 721-50-6, Prilocaine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine 777-11-7, Haloprogin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7, Lincomycin hydrochloride 865-21-4, Vinblastine 866-83-1, Potassium citrate 894-71-3, Nortriptyline hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton 969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafacillin sodium 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride 1094-08-2, Ethopropazine hydrochloride 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9, Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin 1151-11-7, Ipratropium calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Ipratropium sodium 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride 1244-76-4, 1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1309-48-4, Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid 1343-97-1, Selenium sulfate 1393-48-2, Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1404-00-8, Mycomycin 1404-04-2, Neomycin 1404-88-2, Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9, Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8, Phenmetrazine hydrochloride 1808-12-4, Bromo diphenhydramine hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetol 1972-08-3, Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3, Meclocycline 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liquid components into matrix to obtain discrete stable particles)

IT 2098-66-0, Cyproterone 2179-37-5, Bencyclane 2315-02-8, Oxymetazoline

hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cycloacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatidine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4759-48-2, Isotretinoin 4891-15-0, Estramustine phosphate 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, β -Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts 7440-39-3D, Barium, salts 7440-39-9, Bismuth, biological studies 7440-70-2D, Calcium, salts 7447-40-7, Potassium chloride, biological studies 7491-74-9, Piracetam 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide, biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide (NaI), biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8002-55-9, Myrtol 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1 9000-92-4, Amylase 9001-00-7, Bromelin 9001-01-8, Kallidinogenase 9001-62-1, Lipase 9001-73-4, Papain 9001-92-7, Proteinase 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9002-86-2, Polyvinyl chloride 9003-20-7, Polyvinyl acetate 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6, Cellulose, biological studies 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 9012-54-8, Cellulase 9025-49-4 9025-56-3, Hemicellulase 9032-75-1, Pectinase 9068-42-2, Pentosanase 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanozolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin 13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3 14009-24-6, Drotaverine 14028-44-5, Amoxapine 14402-89-2, Sodium nitroprusside 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15307-86-5, Diclofenac 15622-65-8,

Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalexin 15687-27-1 15687-41-9, Oxyfedrine 16034-77-8, Iocetamic acid 16051-77-7 16482-55-6 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrel sulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4, Diflunisal 22916-47-8, Miconazole 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probuco 23593-75-1, Clotrimazole 23869-24-1, O-(β -Hydroxyethyl)rutoxide 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25155-18-4, Methylbenzethonium chloride 25301-02-4, Tyloxapol 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26605-69-6, Carbenicillin indanyl sodium 26652-09-5, Ritodrine 26652-10-8 26675-46-7, Isoflurane 26787-78-0, Amoxycillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepin 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30516-87-1 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0, Etoposide 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 34787-01-4, Ticarcillin 36322-90-4, Piroxicam RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(encapsulation of sensitive liquid components into matrix to obtain discrete shelf-stable particles)

IT 83-73-8, Iodoquinol 136-26-7, Cloquinol

7440-69-9, Bismuth, biological studies

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)

(encapsulation of sensitive liquid components into matrix to obtain discrete shelf-stable particles)

RN 83-73-8 CAPLUS

CN 8-Quinololinol, 5,7-diiodo- (CA INDEX NAME)



RN 130-26-7 CAPLUS

CN 8-Quinololinol, 5-chloro-7-iodo- (CA INDEX NAME)



RN 7440-69-9 CAPLUS
CN Bismuth (CA INDEX NAME)

Bi

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:293427 CAPLUS Full-text
DOCUMENT NUMBER: 129:8597
ORIGINAL REFERENCE NO.: 129:1853a,1856a
TITLE: Embedding and encapsulation of controlled release
particles
INVENTOR(S): Van Lengerich, Bernhard H.
PATENT ASSIGNEE(S): Van Lengerich, Bernhard H., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818610	A1	19980507	WO 1997-US18984	19971027
W: AU, CA, JP, NO, PL, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2269806	A1	19980507	CA 1997-2269806	19971027
CA 2269806	C	20060124		
AU 9749915	A	19980522	AU 1997-49915	19971027
AU 744156	B2	20020214		
EP 935523	A1	19990818	EP 1997-912825	19971027
EP 935523	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511777	T	20020416	JP 1998-520558	19971027
EP 1342548	A1	20030910	EP 2003-10031	19971027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 277739	T	20041015	AT 1997-912825	19971027
PL 191399	B1	20060531	PL 1997-333095	19971027
NO 9902036	A	19990428	NO 1999-2036	19990428
PRIORITY APPLN. INFO.:				
			US 1996-29038P	P 19961028
			US 1997-52717P	P 19970716
			EP 1997-912825	A3 19971027

- AB Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The addnl. component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temperature of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixture. The mixture is extruded through a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, glycerol monostearate, and vegetable oil.
- IC ICM B29C047-04
ICS B01J013-04; A01N025-26
- CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 5
- IT Antibiotics
Antioxidants
Detergents
Emulsifying agents
Extrusion, nonbiological
Fats and Glyceridic oils, biological studies
Fatty acids, biological studies
Flavor
Fungicides
Glass transition
Heat treatment
Herbicides
Hydrocolloids
Insecticides
Lipids, biological studies
Paraffin waxes, biological studies
Peptides, biological studies
Perfumes
Pesticides
Plasticizers
Polyolefins
Polyurethanes, biological studies
Proteins, general, biological studies
Rodenticides
Steroids, biological studies
Surfactants
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(embedding and encapsulation of controlled release particles)
- IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6,
Phenobarbital, biological studies 50-12-4, Mephenytoin 50-14-6,
Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone
50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological

studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine
 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5,
 Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2,
 Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4,
 Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate
 50-63-5, Chloroquine phosphate 50-78-2, Acetylsalicylic acid 50-81-7,
 Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride
 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8,
 Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine
 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies
 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies
 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine
 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9,
 Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa
 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5,
 Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1,
 Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone,
 biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1,
 Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium
 salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-64-8,
 Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1,
 Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan
 56-29-1, Hexobarbital 56-47-3, Desoxycorticosterone acetate 56-53-1,
 Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol
 56-84-8, L-Aspartic acid, biological studies 56-87-1, L-Lysine,
 biological studies 57-13-6, Urea, biological studies 57-22-7,
 Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin
 57-42-1, Meperidine 57-43-2, Amobarbital 57-47-6, Physostigmine
 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9, Probenecid
 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies
 57-92-1, Streptomycin, biological studies 57-96-5, Sulfipyrazone
 58-00-4, Apomorphine 58-08-2, Caffeine, biological studies 58-14-0,
 Pyrimethamine 58-18-4, Methyltestosterone 58-22-0 58-25-3,
 Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyridamole 58-33-3,
 Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9,
 Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9,
 Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride
 58-85-5, Biotin 58-89-9, Lindane 58-93-5, Hydrochlorothiazide
 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid,
 biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin,
 biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid
 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7,
 Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4,
 Tyrosine, biological studies 60-54-8, Tetracycline 60-56-0,
 Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1,
 Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine
 hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine
 hydrochloride 61-90-5, Leucine, biological studies 62-31-7, Dopamine
 hydrochloride 62-44-2, Phenacetin 62-67-9, Nalorphine 62-90-8,
 Mandrolone phenpropionate 63-68-3, Methionine, biological studies
 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine
 hydrochloride 63-98-9, Phenacetamide 64-31-3, Morphine sulfate
 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8,
 Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8,
 Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone
 67-73-2, Flucinolone acetonide 67-96-9, Dihydrotychsterol 67-97-0,
 Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone
 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole
 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4,
 Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1,

Histidine, biological studies 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8
 72-14-0, Sulfathiazole 72-17-3, Sodium lactate 72-18-4, Valine, biological studies 72-19-5, L-Threonine, biological studies 72-33-3, Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan, biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-44-4, Carisoprodol 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-22-0, Tetrahydrozoline 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Phenoxymethylpenicillin 87-33-2, ISDN 89-57-6, 5-Aminosalicylic acid 90-33-5, Hymecromone 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripeleennamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzene 103-86-6, Hydroxyamphetamine 103-90-2, Acetaminophen 104-28-9, Cinoxate 104-31-4, Benzonatate 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital 115-77-5, biological studies 120-97-8, Dichlorphenamide 121-25-5, Amprolium

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

IT 121-54-0 121-75-5, Malathion 123-31-9, 1,4-Benzenediol, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docosate calcium 128-62-1, Noscaphine 129-20-4, Oxyphenbutazone 129-49-7, Methylsergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clioquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-47-0 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital sodium 144-14-9, Anileridine 144-48-9, Iodoacetamide 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-24-0, Diphenhydramine hydrochloride 147-52-4, Nafcillin 147-85-3, Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 152-97-6, Fluocortolone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline

298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride
 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous
 gluconate 299-42-3, Ephedrin 302-22-7, Chlormadinone acetate
 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1,
 Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate,
 biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital
 sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9
 329-65-7, 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]- 343-55-5,
 Diclloxacinil sodium 345-78-8, Pseudoephedrine hydrochloride 346-18-9,
 Polythiazide 356-12-7, Flucaninone 357-07-3, Oxymorphone
 hydrochloride 359-83-1, Pentazocine 360-70-3, Nandrolone decanoate
 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine
 hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate
 382-67-2, Desoximetasone 389-08-2, Nalidixic acid 390-64-7,
 Prenylamine 396-01-0, Triamterene 426-13-1, Fluorometholone
 434-07-1, Oxymetholone 435-97-2, Phenprocoumon 437-74-1, Xantiniol
 nicotinate 439-14-5, Diazepam 440-17-5, Trifluoperazine hydrochloride
 443-48-1, Metronidazole 446-86-6, Azathioprine 465-65-6, Naloxone
 466-99-9, Hydromorphone 471-34-1, Calcium carbonate, biological studies
 474-86-2, Equilin 479-18-5, Dyphylline 484-23-1, Dihydroalazine
 486-12-4, Triprolidine 511-12-6, Dihydroergotamine 514-36-3,
 Fludrocortisone acetate 514-65-8, Biperiden 518-47-8, Fluorescein
 sodium 519-37-9, Etofylline 520-85-4, Medroxyprogesterone 523-87-5,
 Dimenhydrinate 525-66-6, Propranolol 527-07-1, Sodium gluconate
 532-03-6, Methocarbamol 533-45-9, Clomethiazole 536-21-0, Norfenefrine
 536-33-4, Ethionamide 541-15-1, Levocarnitine 546-88-3,
 Acetohydroxamic acid 546-93-0, Magnesium carbonate 548-62-9, Gentian
 violet 548-73-2, Droperidol 549-18-8, Amitriptyline hydrochloride
 550-83-4, Propoxycaïne hydrochloride 551-27-9, Propicillin 552-94-3,
 Salsalate 554-13-2, Lithium carbonate 554-57-4, Methazolamide
 554-92-7, Trimethobenzamide hydrochloride 555-30-6, Methylodopa
 557-34-6, Zinc acetate 562-10-7 564-25-0, Doxycycline 577-11-7,
 Docusate sodium 579-56-6, Isoxsuprine hydrochloride 587-61-1,
 Propylidone 590-63-6, Bethanechol chloride 595-33-5, Megestrol
 acetate 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 599-88-2,
 Sulfaperin 603-50-9, Bisacodyl 604-75-1, Oxazepam 614-39-1,
 Procaïnamide hydrochloride 616-91-1, Acetylcysteine 620-61-1,
 Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate 637-07-0,
 Clofibrate 637-58-1, Pramoxine hydrochloride 638-23-3 642-78-4,
 Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 652-67-5 672-87-7,
 Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine 723-46-6,
 Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3, Alprostadil
 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine 777-11-7,
 Haloproglin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine
 hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7,
 Lincomycin hydrochloride 865-21-4, Vinblastine 894-71-3, Nortriptyline
 hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton
 969-33-5, Cyproheptadine hydrochloride 985-16-0, Naficillin sodium
 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride
 1077-28-7, Thioctic acid 1094-08-2, Ethopropazine hydrochloride
 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9,
 Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin
 1151-11-7, Ipratide calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin
 sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Ipratide sodium
 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride
 1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1309-48-4,
 Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid
 1321-23-9, Chloroxylenol 1343-97-1, Selenium sulfate 1393-48-2,
 Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candididin 1403-66-3,
 Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2,

Tyrosine 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin B sulfate 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9, Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8, Phenmetrazine hydrochloride 1808-12-4, Bromodiphenhydramine hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3, Dronabinol 1977-10-2, Loxapine

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(embedding and encapsulation of controlled release particles)

- IT 1982-37-2, Methdilazine 2013-58-3, Meclizine 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2098-66-0, Cyproterone 2179-37-5, Bencyclane 2192-20-3, Hydroxyzine hydrochloride 2315-02-8, Oxmetazoline hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 2955-38-6, Prazepam 2998-57-4, Estramustine 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cycloacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatidine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-04-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 6890-40-0, Histamine phosphate 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, β -Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts, biological studies 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts, biological studies 7440-39-3, Barium, biological studies 7440-69-9, Bismuth, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride (KCl), biological studies 7491-74-9, Piracetam 7553-56-2, Iodine, biological studies 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide (KI), biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide, biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7778-49-6, Potassium citrate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8049-47-6, Pancreatins 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1, Ergoloid mesylates 9001-01-8, Kallidinogenase 9001-73-4, Papain 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies

9002-61-3, Chorionic gonadotropin 9002-86-2, Pvc 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8, Pvp 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-53-9, Dextrin 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetracepam 10418-03-8, Stanozolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12619-70-4, Cyclodextrin 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin 13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3, Dihydroxyaluminum aminoacetate 14009-24-6, Drotaverine 14028-44-5, Amoxapine 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15078-28-1, Nitroprusside 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpuride 15686-51-8, Clemastine 15686-71-2, Cephalixin 15687-27-1 15687-41-9, Oxfedrine 16482-55-6, Dihydroxyaluminum sodium carbonate 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrelisulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4 22916-47-8 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probuco 23593-75-1, Clotrimazole 23869-24-1, O-(β -Hydroxyethyl)-rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25086-89-9, Vinyl acetate-N-vinylpyrrolidinone copolymer 25155-18-4, Methylbenzethonium chloride 25167-80-0, Chlorophenol 25301-02-4, Tyloxapol 25322-68-3 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25717-80-0, Molsidomine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxonyl 9 26171-23-3, Tolmetin 26652-09-5, Ritodrine 26675-46-7, Isoflurane 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepine 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0 33996-33-7, Oxaceprol 34031-32-8, Auranofin

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 83-73-8, Iodoquinol 130-36-7, Clloquinol
7440-69-9, Bismuth, biological studies

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

RN 83-73-8 CAPLUS

CN 8-Quinololinol, 5,7-diiodo- (CA INDEX NAME)



RN 130-26-7 CAPLUS

CN 8-Quinololinol, 5-chloro-7-iodo- (CA INDEX NAME)



RN 7440-69-9 CAPLUS

CN Bismuth (CA INDEX NAME)

Bi

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:558050 CAPLUS Full-text

DOCUMENT NUMBER: 127:248025

ORIGINAL REFERENCE NO.: 127:48461a,48464a

TITLE: Preparation of cyanoquinoline from methylquinoline at gas phase

INVENTOR(S): Utsumi, Hiroshi; Morii, Akimitsu

PATENT ASSIGNEE(S): Nitto Chemical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
JP 09216870	A	19970819	JP 1996-46926	19960209
PRIORITY APPLN. INFO.:			JP 1996-46926	19960209
OTHER SOURCE(S):		CASREACT 127:248025		

AB Cyanoquinoline (I) is prepared by treatment of methylquinoline (II) with NH₃ and O in the presence of metal oxides at gas phase. 2-II was subjected to gas-phase ammoxidn. at 430° over V₅Fe₁₀Sb₂₀Cr₂P₀.5071.75(SiO₂)₅₀ as fluidized bed catalyst to give 69.3% 2-I.

IC ICM C07D215-48
ICS B01J023-847; B01J023-88; B01J027-198; B01J027-199; C07B061-00

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

IT 195513-32-7 195513-33-8 195513-34-9 195513-35-0 195513-36-1
195513-37-2 195513-38-3
RL: CAT (Catalyst use); USES (Uses)
(reparation of cyanoquinoline from methylquinoline at gas phase with metal oxide catalysts)

IT 1436-43-7P, 2-Cyanoquinoline 34846-64-5P, 3-Cyanoquinoline
64850-00-6P, Quinolinecarbonitrile
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(reparation of cyanoquinoline from methylquinoline at gas phase with metal oxide catalysts)

IT 91-63-4, 2-Methylquinoline 612-56-8, 3-Methylquinoline
7664-41-7, Ammonia, reactions 27601-00-9, Methylquinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(reparation of cyanoquinoline from methylquinoline at gas phase with metal oxide catalysts)

IT 195513-38-3
RL: CAT (Catalyst use); USES (Uses)
(reparation of cyanoquinoline from methylquinoline at gas phase with metal oxide catalysts)

RN 195513-38-3 CAPLUS

CN Antimony bismuth iron potassium vanadium oxide (CA INDEX NAME)

Component	Ratio	Component Registry Number
O	x	17778-80-2
Bi	x	7440-69-9
V	x	7440-62-2
Sb	x	7440-36-0
K	x	7440-09-7
Fe	x	7439-89-6

IT 64850-00-6P, Quinolinecarbonitrile
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(reparation of cyanoquinoline from methylquinoline at gas phase with metal oxide catalysts)

RN 64850-00-6 CAPLUS

CN Quinolinecarbonitrile (CA INDEX NAME)




D1-CN

IT 91-63-4, 2-Methylquinoline 612-56-8, 3-Methylquinoline
27601-00-9, Methylquinoline
RL: RCT (Reactant); RACT (Reactant or reagent)

(reparation of cyanoquinoline from methylquinoline at gas phase with metal oxide catalysts)


RN 91-63-4 CAPLUS

CN Quinoline, 2-methyl- (CA INDEX NAME)



RN 612-58-8 CAPLUS

CN Quinoline, 3-methyl- (CA INDEX NAME)



RN 27601-00-9 CAPLUS

CN Quinoline, methyl- (CA INDEX NAME)



D1-Me

L60 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:747587 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 126:103958

ORIGINAL REFERENCE NO.: 126:20057a,20060a

TITLE: Bismuth(III) carboxylates as a new class of oxidants: pyridinecarboxylates and aromatic dicarboxylates in the

oxidative cleavage of aryl epoxides and α -ketols
Coin, Christine; Zevaco, Thomas; Dunach, Elisabeth;
Postel, Michele

CORPORATE SOURCE: Lab. Chimie Moleculaire, Univ. Nice-sophia-Antipolis,
Nice, 06108, Fr.

SOURCE: Bulletin de la Societe Chimique de France (1996),
133(9), 913-918

CODEN: BSCFAS; ISSN: 0037-8968

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several Bi(III) carboxylates have been obtained through reaction of Bi₂O₃ with various pyridinemono- or -dicarboxylic acids, and with phthalic acid. Thus, the tris-carboxylato complex Bi[qui(COO)]₃ forms in the presence of quinaldic acid, while phthalic acid yields Bi[phthal(COO)₂](OH) independently of the stoichiometry of the reaction. A Bi(III) diphenate, PhBi(diphen), was prepared from BiPh₃ and diphenic acid. These were all found to catalyze the oxidative C-C cleavage of styrene oxide and α -hydroxyacetophenone to benzoic

acid. This allowed us to demonstrate that the bismuth-catalyzed oxidation of styrene oxide to benzoic acid goes through the intermediate formation of (i) the α -ketol, PhCOCH_2OH , which requires DMSO as the oxidant, and (ii) the ketoaldehyde, PhCOCHO , which results from Bi(III) -catalyzed dioxygen oxidation of the ketol.

CC 27-2 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 22, 25, 78

IT 139700-22-4 186028-03-5

RL: CAT (Catalyst use); USES (Uses)

(bismuth carboxylates as catalysts for oxidative cleavage of aryl epoxides and α -ketols)

IT 186028-01-3P 186028-05-7P 186028-07-9P

RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP

(Preparation); USES (Uses)

(bismuth carboxylates as catalysts for oxidative cleavage of aryl epoxides and α -ketols)

IT 88-99-3, 1,2-Benzenedicarboxylic acid, reactions 93-10-7, Quinaldic acid 96-09-3, Styrene oxide 482-05-3, Diphenic acid 582-24-1, 2-Hydroxyacetophenone 1304-76-3, Dibismuth trioxide, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(bismuth carboxylates as catalysts for oxidative cleavage of aryl epoxides and α -ketols)


IT 139700-22-4 186028-03-5

RL: CAT (Catalyst use); USES (Uses)

(bismuth carboxylates as catalysts for oxidative cleavage of aryl epoxides and α -ketols)


RN 139700-22-4 CAPLUS

CN Bismuth, tris(2-pyridinecarboxylato- $\kappa\text{N1}, \kappa\text{O2}$)- (CA INDEX NAME)




RN 186028-03-5 CAPLUS


CN Bismuthate(2-), hydroxybis[2,6-pyridinedicarboxylato(2-)- $\kappa\text{N1}, \kappa\text{O2}$]-, dihydrogen (9CI) (CA INDEX NAME)




IT 186028-01-3P 186028-05-7P 186028-07-9P
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP
 (Preparation); USES (Uses)
 (bismuth carboxylates as catalysts for oxidative cleavage of aryl
 epoxides and α -ketols)
 RN 186028-01-3 CAPLUS
 CN Bismuth, tris(2-quinolinecarboxylato- κ N1, κ O2)- (CA INDEX
 NAME)




RN 186028-05-7 CAPLUS
 CN 2,4,3-Benzodioxabismepin-1,5-dione, 3-hydroxy- (CA INDEX NAME)



RN 186028-07-9 CAPLUS
 CN Dibenzo[e,g][1,3,2]dioxabismenin-5,9-dione, 7-phenyl- (CA INDEX NAME)



IT 93-10-7, Quinaldic acid 1304-76-3, Dibismuth trioxide, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (bismuth carboxylates as catalysts for oxidative cleavage of aryl epoxides and α -ketols)
 RN 93-10-7 CAPLUS
 CN 2-Quinolinedicarboxylic acid (CA INDEX NAME)



RN 1304-76-3 CAPLUS
 CN Bismuth oxide (Bi2O3) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:967657 CAPLUS Full-text
 DOCUMENT NUMBER: 124:145411
 ORIGINAL REFERENCE NO.: 124:27041a, 27044a
 TITLE: Preparation of monoolefins by oxydehydrogenation of paraffins
 INVENTOR(S): Io, Hirobumi; Kotani, Makoto
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07247227	A	19950926	JP 1994-40265	19940311
PRIORITY APPLN. INFO.:			JP 1994-40265	19940311

OTHER SOURCE(S): CASREACT 124:145411

AB The title compds. are prepared by gas-phase oxydehydrogenation of paraffins by O2 or O and NH3 using tungstophosphoric acids. A reactor containing Cs-containing H3PW12O40 was fed with propane-O-NH3 at 430° for 20 h to give propylene in 65.7% selectivity at 15.2% conversion.

IC ICM C07C011-02
 ICS B01J023-30; B01J027-186; C07C005-48; C07C011-06; C07C011-09

ICA C07B061-00
 CC 23-2 (Aliphatic Compounds)
 IT 91-22-5D, Quinoline, reaction products with tungstophosphoric acid
 110-86-1D, Pyridine, reaction products with tungstophosphoric acid
 7429-90-5D, Aluminum, reaction products with tungstophosphoric acid
 7439-89-6D, Iron, reaction products with tungstophosphoric acid
 7439-92-1D, Lead, reaction products with tungstophosphoric acid
 7439-96-5D, Manganese, reaction products with tungstophosphoric acid
 7439-98-7D, Molybdenum, reaction products with tungstophosphoric acid
 7439-99-8D, Neptunium, reaction products with tungstophosphoric acid
 7440-02-0D, Nickel, reaction products with tungstophosphoric acid
 7440-03-1D, Niobium, reaction products with tungstophosphoric acid
 7440-06-4D, Platinum, reaction products with tungstophosphoric acid
 7440-15-5D, Rhenium, reaction products with tungstophosphoric acid
 7440-16-6D, Rhodium, reaction products with tungstophosphoric acid
 7440-23-5D, Sodium, reaction products with tungstophosphoric acid
 7440-25-7D, Tantalum, reaction products with tungstophosphoric acid
 7440-26-8D, Technetium, reaction products with tungstophosphoric acid
 7440-28-0D, Thallium, reaction products with tungstophosphoric acid
 7440-29-1D, Thorium, reaction products with tungstophosphoric acid
 7440-31-5D, Tin, reaction products with tungstophosphoric acid
 7440-32-6D, Titanium, reaction products with tungstophosphoric acid
 7440-36-0D, Antimony, reaction products with tungstophosphoric acid
 7440-38-2D, Arsenic, compds. 7440-41-7D, Beryllium, reaction products
 with tungstophosphoric acid 7440-42-8D, Boron, reaction products with
 tungstophosphoric acid 7440-43-9D, Cadmium, reaction products with
 tungstophosphoric acid 7440-45-1D, Cerium, reaction products with
 tungstophosphoric acid 7440-46-2D, Cesium, reaction products with
 tungstophosphoric acid 7440-47-3D, Chromium, reaction products with
 tungstophosphoric acid 7440-48-4D, Cobalt, reaction products with
 tungstophosphoric acid 7440-50-8D, Copper, reaction products with
 tungstophosphoric acid 7440-55-3D, Gallium, reaction products with
 tungstophosphoric acid 7440-56-4D, Germanium, compds. 7440-61-1D,
 Uranium, reaction products with tungstophosphoric acid 7440-62-2D,
 Vanadium, reaction products with tungstophosphoric acid 7440-66-6D,
 Zinc, reaction products with tungstophosphoric acid 7440-67-7D,
 Zirconium, reaction products with tungstophosphoric acid
 7440-69-9D, Bismuth, reaction products with tungstophosphoric acid
 7440-74-6D, Indium, reaction products with tungstophosphoric acid
 7553-56-2D, Iodine, compds. 7782-49-2D, Selenium, compds. 13494-80-9D,
 Tellurium, compds. 92665-66-2 150276-34-9 173532-93-9 173532-94-0
 173532-95-1 173532-96-2 173532-97-3 173532-98-4 173532-99-5
 173533-00-1 173533-01-2 173533-02-3 173533-03-4
 RL: CAT (Catalyst use); USES (Uses)
 (preparation of monoolefins by oxydehydrogenation of paraffins with O2 or
 O2-NH3 using tungstophosphoric acid amine or alkali metal salts as
 catalysts)
 IT 91-22-5D, Quinoline, reaction products with tungstophosphoric acid
 7440-69-9D, Bismuth, reaction products with tungstophosphoric acid
 RL: CAT (Catalyst use); USES (Uses)
 (preparation of monoolefins by oxydehydrogenation of paraffins with O2 or
 O2-NH3 using tungstophosphoric acid amine or alkali metal salts as
 catalysts)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)



RN 7440-69-9 CAPLUS
CN Bismuth (CA INDEX NAME)

Bi

L60 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:516890 CAPLUS Full-text
DOCUMENT NUMBER: 111:116890
ORIGINAL REFERENCE NO.: 111:19595a,19598a
TITLE: Tin or bismuth complex catalysts and trigger cure of
polyurethane coatings therewith
INVENTOR(S): Dammann, Laurence G.; Carlson, Gary M.
PATENT ASSIGNEE(S): Ashland Oil, Inc., USA
SOURCE: U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 844,810,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4788083	A	19881129	US 1986-931610	19861117
AU 8768684	A	19871015	AU 1987-68684	19870211
AU 575741	B2	19880804		
GB 2188327	A	19870930	GB 1987-3528	19870216
GB 2188327	B	19900704		
IN 168614	A1	19910504	IN 1987-DE154	19870223
ES 2004125	A6	19881201	ES 1987-773	19870318
SE 8701195	A	19870928	SE 1987-1195	19870323
SE 466138	B	19920107		
SE 466138	C	19920514		
DE 3709631	A1	19871015	DE 1987-3709631	19870324
DE 3709631	C2	19921126		
DK 8701511	A	19870928	DK 1987-1511	19870325
DK 167619	B1	19931129		
NO 8701251	A	19870928	NO 1987-1251	19870325
NO 169547	B	19920330		
NO 169547	C	19920708		
FR 2596292	A1	19871002	FR 1987-4163	19870325
FR 2596292	B1	19920807		
BE 1001374	A3	19891017	BE 1987-306	19870325
IL 82003	A	19910718	IL 1987-82003	19870325
CA 1303015	C	19920609	CA 1987-533010	19870325
RU 2024553	C1	19941215	RU 1987-4202202	19870325
FI 8701338	A	19870928	FI 1987-1338	19870326
FI 93849	B	19950228		
FI 93849	C	19950612		
NL 8700713	A	19871016	NL 1987-713	19870326

NL 194044	B	20010102		
NL 194044	C	20010503		
BR 8701388	A	19871229	BR 1987-1388	19870326
HU 44449	A2	19880328	HU 1987-1330	19870326
HU 207745	B	19930528		
AT 8700739	A	19940515	AT 1987-739	19870326
CN 87102399	A	19871007	CN 1987-102399	19870327
CN 1007256	B	19900321		
JP 62236816	A	19871016	JP 1987-73954	19870327
JP 04064610	B	19921015		
DD 270868	A5	19890816	DD 1987-301210	19870327
CH 672750	A5	19891229	CH 1987-1178	19870327
DD 283635	A5	19901017	DD 1987-326943	19870327
SE 9001182	A	19911001	SE 1990-1182	19900330
SE 504870	C2	19970520		
NO 9005168	A	19870928	NO 1990-5168	19901129
NO 308257	B1	20000821		

PRIORITY APPLN. INFO.:

US 1986-844810	A2 19860327
US 1986-931610	A 19861117
NO 1987-1251	A1 19870325

AB Catalysts prepared by the reaction of Ti or Bi compds. with a mercapto compound and/or a polyphenol with adjacent OH groups are added to polyol-isocyanate coating compns., giving compns. which have a long pot life and cure rapidly upon heating and/or contact with amine vapor. A composition containing Imron 817U (polyol) 82.5, Imron 192S (polyisocyanate) 27.5, and a 1:9:10:10 dibutyltin dilaurate-ethylene bis(3-mercaptopropionate) (I)-Me amyl ketone-BuOAc mixture 0.66 part had viscosity 43, 53, and 240 cP after 0, 8, and 30 h, resp., vs. gelling during 90 min without I and during 30 h with no catalyst mixture. Spraying the composition on glass and curing in contact with Me2NCH2CH2OH for 5 min at 82.2° gave a coating with MEK resistance 200 double rubs, vs. 200 without I and 120 with no catalyst mixture.

IC ICM B01J031-00

ICS B05D003-04; C08G018-22

INCL 427340000

CC 42-3 (Coatings, Inks, and Related Products)

IT 56-36-0, Tributyltin acetate 59-52-9, 2,3-Dimercaptopropanol 60-24-2, 2-Mercaptoethanol 68-11-1, Mercaptoacetic acid, uses and miscellaneous 75-50-3, Trimethylamine, uses and miscellaneous 77-58-7, Dibutyltin dilaurate 79-42-5, Thiolactic acid 87-66-1, Pyrogallol 91-22-5, Quinoline, uses and miscellaneous 98-94-2, N,N-Dimethylcyclohexylamine 100-37-8, Diethylethanolamine 100-53-8, Benzyl mercaptan 100-74-3, N-Ethylmorpholine 102-69-2, Tripropylamine 102-71-6, uses and miscellaneous 102-82-9, Tributylamine 103-83-3, N,N-Dimethylbenzylamine 105-09-9, α,α' -Dimercapto-p-xylene 106-45-6 108-01-0 108-75-8 108-98-5, Thiophenol, uses and miscellaneous 110-18-9 110-86-1, Pyridine, uses and miscellaneous 111-42-2, uses and miscellaneous 111-88-6, 1-Octanethiol 111-92-2, Dibutylamine 119-65-3, Isoquinoline 120-53-6, 6-Ethoxy-2-mercaptopbenzothiazole 120-80-9, 1,2-Benzenediol, uses and miscellaneous 121-44-8, uses and miscellaneous 123-81-9 124-68-5, 2-Amino-2-methylpropanol 147-93-3, Thiosalicylic acid 280-57-9, 1,4-Diazabicyclo[2.2.2]octane 301-10-0, Stannous octoate 496-74-2, 3,4-Dimercaptotoluene 507-09-5, Thioacetic acid, uses and miscellaneous 595-90-4, Tetraphenyltin 598-56-1 638-39-1, Stannous acetate 753-73-1, Dimethyltin dichloride 769-40-4, 2,3,5,6-Tetrafluorothiophenol 814-94-8, Stannous oxalate 818-08-6, Dibutyltin oxide 870-23-5, Allyl mercaptan 934-00-9, 3-Methoxycatechol 1067-33-0 1191-08-8, 1,4-Butanedithiol 1191-43-1, 1,6-Hexanedithiol 1345-87-9, Bismuth sulfide (Bi2S3) 1461-25-2, Tetrabutyltin 1569-69-3, Cyclohexyl mercaptan 2057-49-0, 4-Phenylpropylpyridine 2150-02-9 2365-48-2,

Methyl thioglycolate 4731-77-5, Dibutyltin dioctoate 4802-20-4
 6493-69-2, Stannous citrate 6892-68-8, Dithioerythritol 7575-23-7
 7646-78-8, Stannic chloride, uses and miscellaneous 7772-99-8, Stannous
 chloride, uses and miscellaneous 10193-96-1, Trimethylolpropane
 tris(thioglycolate) 10361-44-1 18282-10-5, Stannic oxide
 22504-50-3, Ethylene glycol bis(3-mercaptopropionate) 26914-40-9,
 Ethanedithiol 30232-12-3, Mercaptopropionic acid 33007-83-9,
 Trimethylolpropane tris(3-mercaptopropionate) 34364-26-6
 69631-07-8 69631-08-9, Benzothiazodithiol 122532-18-7,
 Dodecanedithiol
 RL: CAT (Catalyst use); USES (Uses)
 (catalysts, for curing of isocyanate-polyol coatings)
 IT 25248-42-4D, Polycaprolactone, triol derivs., polymers with isocyanates
 92457-24-3 113151-33-0 113151-34-1
 113151-35-2 113151-36-3D, reaction products with mercaptopropionic acid
 113151-38-5 113151-39-6 122485-63-6
 122485-64-7 122545-35-1 122545-36-2D, reaction products with
 mercaptopropionic acid 122545-37-3
 RL: TEM (Technical or engineered material use); USES (Uses)
 (coatings, curing catalysts for)
 IT 91-22-5, Quinoline, uses and miscellaneous 1345-07-9,
 Bismuth sulfide (Bi₂S₃) 10361-44-1 34364-26-6
 RL: CAT (Catalyst use); USES (Uses)
 (catalysts, for curing of isocyanate-polyol coatings)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)




RN 1345-07-9 CAPLUS
 CN Bismuth sulfide (Bi₂S₃) (CA INDEX NAME)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 10361-44-1 CAPLUS
 CN Nitric acid, bismuth(3+) salt (3:1) (CA INDEX NAME)



● 1/3 Bi(III)

RN 34364-26-6 CAPLUS
 CN Neodecanoic acid, bismuth(3+) salt (3:1) (CA INDEX NAME)




● 1/3 Bi(III)

IT 83457-24-3 113151-33-0 113151-34-1
 113151-39-6 122465-63-6 122485-64-7
 RL: TEM (Technical or engineered material use); USES (Uses)
 (coatings, curing catalysts for)
 RN 83457-24-3 CAPLUS
 CN 1,2-Benzenedicarboxylic acid, polymer with 1,4-butanediol,
 1,6-diisocyanatohexane, 2-ethyl-2-(hydroxymethyl)-1,3-propanediol and
 hexanedioic acid (9CI) (CA INDEX NAME)

CM 1

CRN 822-06-0


CMF C8 H12 N2 O2



CM 2

CRN 124-04-9

CMF C6 H10 O4



CM 3

CRN 110-63-4

CMF C4 H10 O2



CM 4

CRN 88-99-3


CMF C8 H6 O4



CM 5

CRN 77-99-6

CMF C6 H14 O3



RN 113151-33-0 CAPLUS

CN 1,2-Benzenedicarboxylic acid, polymer with 1,4-butanediol, Desmodur N
3390, 2-ethyl-2-(hydroxymethyl)-1,3-propanediol and hexanedioic acid (9CI)
(CA INDEX NAME)

CM 1

CRN 96510-63-3

CMF Unspecified


CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 124-04-9


CMF C6 H10 O4



CM 3

CRN 110-63-4

CMF C4 H10 O2



CM 4

CRN 88-99-3


CMF C8 H6 O4



CM 5

CRN 77-99-6

CMF C6 H14 O3



RN 113151-34-1 CAPLUS

CN Desmodur N 3390, polymer with K-Flex 188 (9CI) (CA INDEX NAME)

CM 1

CRN 104075-01-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 96510-63-3

CMF Unspecified

CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 113151-39-6 CAPLUS

CN Poly[oxy(1-oxo-1,6-hexanediyl)], α -hydro- ω -hydroxy-, ester
 with 2-ethyl-2-(hydroxymethyl)-1,3-propanediol (3:1), polymer with
 Desmodur N 3390 (9CI) (CA INDEX NAME)

CM 1

CRN 96510-63-3

CMF Unspecified

CCI MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 54735-63-6

CMF (C6 H10 O2)n (C6 H10 O2)n (C6 H10 O2)n C6 H14 O3

CCI PMS



RN 122485-63-6 CAPLUS


CN Poly[oxy(1-oxo-1,6-hexanediyl)], α -hydro- ω -hydroxy-, ester with 2-ethyl-2-(hydroxymethyl)-1,3-propanediol (3:1), polymer with 1,6-diisocyanatohexane trimer (9CI) (CA INDEX NAME)

CM 1

CRN 54735-63-6

CMF (C6 H10 O2)_n (C6 H10 O2)_n (C6 H10 O2)_n C6 H14 O3

CCI PMS



CM 2

CRN 28574-90-5


CMF (C8 H12 N2 O2)₃

CCI PMS

CM 3

CRN 822-06-0

CMF C8 H12 N2 O2



RN 122485-64-7 CAPLUS

CN Hexane, 1,6-diisocyanato-, trimer, polymer with K-Flex 188 (9CI) (CA INDEX NAME)

CM 1

CRN 104075-01-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 28574-90-5
 CMF (C8 H12 N2 O2)3
 CCI PMS

CM 3

CRN 822-06-0
 CMF C8 H12 N2 O2

OCH—(CH₂)₆—NCO

L60 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:474109 CAPLUS Full-text

DOCUMENT NUMBER: 109:74109

ORIGINAL REFERENCE NO.: 109:12425a,12428a

TITLE: Catalysts for the polymerization of phosphazenes

INVENTOR(S): Maruyama, Isao; Katsuta, Masatoshi; Ito, Zenji;

Noguchi, Takeshi; Furukawa, Masayuki

PATENT ASSIGNEE(S): Maruzen Petrochemical Co., Ltd., Japan; Shin Nisso
 Kako Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63041537	A	19880222	JP 1986-186164	19860808
JP 06047448	B	19940622		

PRIORITY APPLN. INFO.: JP 1986-186164 19860808

AB Hexachlorocyclotriphosphazene (I) and/or octachlorocyclotetraphosphazene are heated in the presence of catalysts containing SO₄ groups to prepare soluble polymers containing no gel at high conversion. Thus, 3.5 g I, 1.7 mol% (based on I) H₂SO₄, and 3.5 mL 1,2,4-trichlorobenzene were sealed in an evacuated tube, heated at 3.5 h at 220°, added to toluene, separated to remove the insolubles, precipitated in heptane, dissolved in toluene, added to diglyme containing p-cresol Na salt at 50-60° with stirring, heated at reflux for 40 h, and precipitated in methanol to give 2.19 g polymer.

IC ICM C08G079-02

CC 35-3 (Chemistry of Synthetic High Polymers)

Section cross-reference(s): 67

IT 64-67-5, Diethyl sulfate 151-63-3 496-45-7 546-74-7 587-84-8,
 Diphenylamine sulfate 1184-66-3 2950-43-8, Hydroxylamine-O-sulfonic
 acid 3597-26-0, Piperazine sulfate 6219-71-2 7487-88-9, Sulfuric
 acid magnesium salt (1:1), uses and miscellaneous 7637-03-8
 7664-93-9D, Sulfuric acid, actinide or Group VIII element salts
 7681-38-1, Sodium bisulfate 7733-02-0, Zinc sulfate 7757-82-6
 7758-98-7, Sulfuric acid copper(2+) salt (1:1), uses and miscellaneous
 7782-78-7, Nitrosyl sulfuric acid 7785-87-7, Manganous sulfate
 7786-81-4 7786-81-4, Nickel sulfate 7787-68-8, Bismuth sulfate
 7803-63-6, Ammonium bisulfate 10028-22-5, Ferric sulfate 10034-93-2,

Hydrazine sulfate 10039-54-0, Hydroxylamine sulfate 10043-01-3,
 Aluminum sulfate 10124-44-4 10343-61-0, Titanous sulfate 10381-37-0
 13597-54-1 14644-61-2 14808-79-8, Sulfate, uses and miscellaneous
 17464-82-3, Semicarbazide sulfate 20305-50-4, Aniline sulfate
 24670-27-7 25723-52-8, Ethylenediamine sulfate 27774-13-6
 32503-27-8, Tetrabutylammonium bisulfate 34114-35-7, Pyridine sulfate
 41949-04-6, Quinoline sulfate 55872-15-6 115865-84-4
 115865-85-5, 1,2,4-Triazole sulfate 115865-86-6 115865-87-7
 115865-88-8 115865-89-9 115865-90-2 115865-91-3

RL: CAT (Catalyst use); USES (Uses)

(catalysts, for polymerization of hexachlorocyclotriphosphazene)

IT 7787-68-0, Bismuth sulfate 41949-04-6, Quinoline sulfate

RL: CAT (Catalyst use); USES (Uses)

(catalysts, for polymerization of hexachlorocyclotriphosphazene)

RN 7787-68-0 CAPLUS

CN Sulfuric acid, bismuth(3+) salt (3:2) (8CI, 9CI) (CA INDEX NAME)



● 2/3 Bi(III)

RN 41949-04-6 CAPLUS

CN Quinoline, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S



CM 2

CRN 91-22-5

CMF C9 H7 N



DOCUMENT NUMBER: 106:83814
 ORIGINAL REFERENCE NO.: 106:13745a,13748a
 TITLE: Nature of active sites of acidic solid catalysts for the oxidative dehydrogenation of ethylbenzene
 AUTHOR(S): Echigoya, E.; Sano, H.; Tanaka, M.
 CORPORATE SOURCE: Tokyo Inst. Technol., Tokyo, 152, Japan
 SOURCE: Int. Congr. Catal., [Proc.], 8th (1984), Volume 5, V623-V633. Verlag Chemie: Weinheim, Fed. Rep. Ger.

CODEN: 55DBAG
 DOCUMENT TYPE: Conference
 LANGUAGE: English

AB Various kinds of acidic catalysts such as Al₂O₃, SiO₂-Al₂O₃, SiO₂-MgO, SiO₂-ZrO₂, Al₂O₃-B₂O₃ and SiO₂ modified with P₂O₅ were used for the oxidative dehydrogenation of ethylbenzene in the vapor phase at 450° using a conventional flow method. These acidic solid catalysts had much higher activities (conversion 60%, selectivity 70%), compared with Bi₂O₃-MoO₃ catalyst which is well known as an excellent catalyst for the oxidative dehydrogenation of butene to butadiene. It is the most important feature of this reaction that the catalytic activity increases with the process time for some time in the beginning of the reaction. The development of active sites of acidic catalysts during the reaction is due to the carbonaceous material formed on the catalyst surface and the major role of the catalyst is to form the carbonaceous material in the initial stage of the reaction.

CC 22-7 (Physical Organic Chemistry)
 Section cross-reference(s): 25

IT 1304-76-3, Bismuth oxide (Bi₂O₃), uses and miscellaneous

RL: CAT (Catalyst use); USES (Uses)

(catalyst, with molybdenum oxide, for oxidative dehydrogenation of ethylbenzene, active sites of)

IT 91-22-5, Quinoline, uses and miscellaneous 110-86-1, Pyridine, uses and miscellaneous

RL: USES (Uses)

(in oxidative dehydrogenation of ethylbenzene on alumina-silica catalyst, active sites in relation to)

IT 1304-76-3, Bismuth oxide (Bi₂O₃), uses and miscellaneous

RL: CAT (Catalyst use); USES (Uses)

(catalyst, with molybdenum oxide, for oxidative dehydrogenation of ethylbenzene, active sites of)

RN 1304-76-3 CAPLUS

CN Bismuth oxide (Bi₂O₃) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 91-22-5, Quinoline, uses and miscellaneous

RL: USES (Uses)

(in oxidative dehydrogenation of ethylbenzene on alumina-silica catalyst, active sites in relation to)

RN 91-22-5 CAPLUS

CN Quinoline (CA INDEX NAME)



ORIGINAL REFERENCE NO.: 104:35759a,35762a
 TITLE: Methacrylic acid
 INVENTOR(S): Wada, Masahiro; Ishii, Toru; Shimazaki, Yoshiharu;
 Ono, Tetsutsugu
 PATENT ASSIGNEE(S): Nippon Shokubai Kagaku Kogyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60239439	A	19851128	JP 1984-94536	19840514
JP 01033097	B	19890711		

PRIORITY APPLN. INFO.: JP 1984-94536 19840514
 OTHER SOURCE(S): CASREACT 104:225353

AB Methacrolein is contacted with O in gas phase in the presence of molybdovanadophosphate catalysts to prepare methacrylic acid. Thus, a catalyst was prepared from MoO₃, V₂O₅, H₃PO₄, La oxide, and KNO₃ in the presence of pyridine and water.

IC ICM C07C057-055
 ICS B01J027-198

CC 35-2 (Chemistry of Synthetic High Polymers)
 Section cross-reference(s): 23, 45

IT 1309-64-4, uses and miscellaneous 1312-81-8 1313-27-5, uses and miscellaneous 1314-36-9, uses and miscellaneous 1314-62-1, uses and miscellaneous 3251-23-8 7664-38-2, uses and miscellaneous 7697-37-2, uses and miscellaneous 7757-79-1, uses and miscellaneous 7761-88-8, uses and miscellaneous 7778-39-4 7789-18-6 7803-55-6 10045-95-1 10102-45-1 10141-05-6 10168-80-6 10361-44-1 10361-80-5 11098-84-3 11120-48-2 12060-58-1 12064-62-9 13126-12-0 13463-67-7, uses and miscellaneous 13465-60-6 13746-89-9 20281-00-9 37382-23-3 39377-54-3
 RL: CAT (Catalyst use); USES (Uses)
 (catalyst component, for oxidation of methacrolein)

IT 91-22-5, uses and miscellaneous 110-85-0, uses and miscellaneous 110-86-1, uses and miscellaneous 110-89-4, uses and miscellaneous 119-65-3 289-95-2
 RL: USES (Uses)
 (manufacture of molybdovanadophosphates in presence of, for catalysts for oxidation of methacrolein)

IT 10361-44-1
 RL: CAT (Catalyst use); USES (Uses)
 (catalyst component, for oxidation of methacrolein)

RN 10361-44-1 CAPLUS

CN Nitric acid, bismuth(3+) salt (3:1) (CA INDEX NAME)



● 1/3 Bi(III)

IT 91-22-5, uses and miscellaneous
 RL: USES (Uses)

(manufacture of molybdo vanadophosphates in presence of, for catalysts for oxidation of methacrolein)

RN 91-22-5 CAPLUS

CN Quinoline (CA INDEX NAME)



L60 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:131969 CAPLUS Full-text

DOCUMENT NUMBER: 104:131969

ORIGINAL REFERENCE NO.: 104:20865a, 20868a

TITLE: Oxidation catalysts

INVENTOR(S): Tsuneki, Hideaki; Uejima, Rikuo

PATENT ASSIGNEE(S): Nippon Shokubai Kagaku Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60209258	A	19851021	JP 1984-63260	19840402
JP 05002376	B	19930112		

PRIORITY APPLN. INFO.: JP 1984-63260 19840402

AB Heteropoly acid catalysts, PaMoVxCdYeOf [$X = \text{K, Rb, Cs, Ca, Sr, and/or Ba; Y} = \text{Cu, Ag, As, Sb, Te, Co, and/or Bi}$; with atomic ratio $a = 0.1\text{--}3.0$, $b = 12$, $c = 0.1\text{--}6.0$, $d = 0.05\text{--}6$, $e = 0.01\text{--}5.0$, and f dependent upon valences of other elements; which produce methacrylic acid (I) by vapor-phase oxidation of C4-aliphatic aldehydes or fatty acids, e.g., methacrolein (II), isobutyraldehyde, isobutyric acid, contain free cubic molybdo vanadophosphoric acid (III). The catalysts are prepared in the presence of quinoline (IV) and/or its derivs. Thus, MoO_3 144.0, V_2O_5 8.278, and 85% H_3PO_4 10.5 g were mixed with 1 L water and refluxed 5 h to obtain III (triclinic crystal; P-Mo-V 1.09:12:1.09), 81.7 g of which was dissolved in 100 mL hot water and mixed with a solution containing 21.5 g IV and 83.3 mL 2 N aqueous HNO_3 to obtain a precipitate. This precipitate was mixed with 4.0 g CsNO_3 and 1.0 g $\text{Cu(NO}_3)_2$, formed into cylinders (diameter 5 mm; height 5 mm), dried at 150° , and baked 4 h at 430° under N then 3 h at 350° in air to obtain an oxide having a cubic crystalline structure (P-Mo-V-Cs-Cu 1.09:12:1.09:0.5:0.1) with compressive strength ≥ 3.0 kg/pellet, BET sp. surface area 10.8 m^2/g , and fine pore volume 0.35 mL/g. Then, 50 mL catalyst was packed in a stainless U-tube (inner diameter 25 mm), immersed in a bath at 280° , and a 1:3:36:10 II-O₂-N₂-steam mixture was introduced into the tube at superficial velocity 2000 h⁻¹, showing II conversion 93.1 mol %, I selectivity 86.7 mol %, and I single pass yield 80.7 mol%, vs. 84.9, 84.5, and 71.7 mol%, resp., without the Cu.

IC ICM B01J027-198

ICS C07C057-05

CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)

Section cross-reference(s): 23, 67

IT 1309-64-4, uses and miscellaneous 1310-82-3 1313-27-5, uses and

miscellaneous 1314-62-1, uses and miscellaneous 3251-23-8 7664-38-2,
 uses and miscellaneous 7757-79-1, uses and miscellaneous 7761-88-8,
 uses and miscellaneous 7778-39-4 7789-18-6 10022-31-8 10042-76-9
 10124-37-5 10141-05-6 10361-44-1 13126-12-0 13520-55-3
 RL: CAT (Catalyst use); USES (Uses)
 (catalysts, for oxidation in methacrylic acid manufacture)
 IT 91-22-5, uses and miscellaneous 119-65-3 27601-00-9
 RL: USES (Uses)
 (in manufacture of molybdovanadophosphoric acid oxidation catalysts)
 IT 10361-44-1
 RL: CAT (Catalyst use); USES (Uses)
 (catalysts, for oxidation in methacrylic acid manufacture)
 RN 10361-44-1 CAPLUS
 CN Nitric acid, bismuth(3+) salt (3:1) (CA INDEX NAME)



● 1/3 Bi(III)

IT 91-22-5, uses and miscellaneous 27601-00-9
 RL: USES (Uses)
 (in manufacture of molybdovanadophosphoric acid oxidation catalysts)
 RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)



RN 27601-00-9 CAPLUS
 CN Quinoline, methyl- (CA INDEX NAME)



D1-Me

L60 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:492893 CAPLUS Full-text
 DOCUMENT NUMBER: 97:92893
 ORIGINAL REFERENCE NO.: 97:15509a,15512a
 TITLE: Study of the principles of the polymerization of
 diisocyanates with 2-substituted furan alcohols
 AUTHOR(S): Magrupov, F. A.; Abdurashidov, T. R.
 CORPORATE SOURCE: Tashk. Politekh. Inst., Tashkent, USSR
 SOURCE: Sint. Poliuretanov (1981), 110-14. Editor(s):

Omel'chenko, S. I. Izd. Naukova Dumka: Kiev, USSR.

CODEN: 48BKA9

DOCUMENT TYPE:

Conference

LANGUAGE:

Russian

- AB The polymerization of 2,4-tolylene diisocyanate with furfuryl or furylallyl alcs. at 373 K in PhCl in the presence of amines or metal salts gave thermosetting amidourethane oligomers having m.p. 423-643 K. Of the 9 catalysts tests triethylamine [121-44-8] and Pb naphthenate gave the best results. The amidourethane oligomers are readily crosslinked at elevated temps. and in the presence of 30% H2SO4 to give heat-resistant polymers.
- CC 35-5 (Chemistry of Synthetic High Polymers)
Section cross-reference(s): 37, 67
- IT 91-22-5, uses and miscellaneous 110-86-1, uses and miscellaneous 121-44-8, uses and miscellaneous 7439-89-6D, salts of naphthenic acid 7439-92-1D, salts of naphthenic acid 7439-96-5D, salts of naphthenic acid 7705-08-0, uses and miscellaneous 7772-99-8, uses and miscellaneous 10361-44-1
RL: CAT (Catalyst use); USES (Uses)
(catalysts, for polymerization of furan derivs. with tolylene diisocyanate)
- IT 91-22-5, uses and miscellaneous 10361-44-1
RL: CAT (Catalyst use); USES (Uses)
(catalysts, for polymerization of furan derivs. with tolylene diisocyanate)
- RN 91-22-5 CAPLUS
- CN Quinoline (CA INDEX NAME)



RN 10361-44-1 CAPLUS

CN Nitric acid, bismuth(3+) salt (3:1) (CA INDEX NAME)



● 1/3 Bi(III)

L60 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:181479 CAPLUS Full-text

DOCUMENT NUMBER: 92:181479

ORIGINAL REFERENCE NO.: 92:29416h,29417a

TITLE: Dehydrobromination of 7-bromocholest-5-en-3 β -ol benzoate

AUTHOR(S): Yakhimovich, R. I.; Kurchenko, L. K.; Krisal'naya, L. A.

CORPORATE SOURCE: Inst. Biokhim. im. Palladina, Kiev, USSR

SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1979), 13(11), 63-6

CODEN: KHFZAN; ISSN: 0023-1134


DOCUMENT TYPE: Journal

LANGUAGE: Russian

- AB Strength of individual particles of several pharmaceutical powders (0.4-0.5 mm) was examined. The strength of these particles ranged from 0.5 + 106-2 + 107 N/m², particles of crystalline nature having more strength than their amorphous counterparts. Dispersibility of sulfanilamide [63-74-1], H3BO3, and S in petrolatum was examined at 10% concentration with average particle size of 1-5 mm. The expts. were conducted at 50°. Microscopic anal. of the ointment showed that strength of the individual particle correlated well with dispersion process. Importance of average particle size of S was evident earlier than the greater strength of particles of sulfanilamide and H3BO3. Under the exptl. conditions used, lower strength of the dispersing particles corresponded with lesser average diameter of the particles.
- CC 32-6 (Steroids)
- IT 91-22-5, uses and miscellaneous 91-63-4 108-48-5
108-75-8 108-89-4 108-99-6 109-06-8 110-86-1, uses and
miscellaneous 121-45-9 122-52-1 491-35-0 589-93-5
612-60-2 1606-96-8
RL: CAT (Catalyst use); USES (Uses)
(catalysts, for dehydrobromination of bromocholestenol benzoate)
- IT 50-03-3 50-78-2 50-99-7, properties 58-15-1 58-55-9, properties
60-54-8 63-74-1 65-45-2 69-72-7, properties 79-57-2 82-02-0
103-90-2 317-34-0 471-34-1, properties 497-19-8, properties
513-77-9 621-72-7 1314-13-2, properties 2787-09-9 5175-83-7
7100-07-4 7704-34-9, properties 7727-43-7 8000-95-1 9005-25-8,
properties 10043-35-3, properties 10361-44-1 27942-00-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(powder, strength of, dispersibility and particle size in relation to)
- IT 91-22-5, uses and miscellaneous 91-63-4 491-35-0
612-60-2
RL: CAT (Catalyst use); USES (Uses)
(catalysts, for dehydrobromination of bromocholestenol benzoate)
- RN 91-22-5 CAPLUS
- CN Quinoline (CA INDEX NAME)




- RN 91-63-4 CAPLUS
- CN Quinoline, 2-methyl- (CA INDEX NAME)




- RN 491-35-0 CAPLUS
- CN Quinoline, 4-methyl- (CA INDEX NAME)



RN 612-60-2 CAPLUS
CN Quinoline, 7-methyl- (CA INDEX NAME)



IT 5175-83-7 10361-44-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(powder, strength of, dispersibility and particle size in relation to)
RN 5175-83-7 CAPLUS
CN Phenol, 2,4,6-tribromo-, bismuth(3+) salt (3:1) (CA INDEX NAME)



● 1/3 Bi(III)

RN 10361-44-1 CAPLUS
CN Nitric acid, bismuth(3+) salt (3:1) (CA INDEX NAME)



● 1/3 Bi(III)

L60 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:482057 CAPLUS Full-text
DOCUMENT NUMBER: 71:82057
ORIGINAL REFERENCE NO.: 71:15265a,15268a
TITLE: Nonforaminous polychloral
INVENTOR(S): Vogl, Otto F.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co.
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3454527	A	19690708	US 1965-508569	19651118

PRIORITY APPLN. INFO.:

US 1965-508569

A 19651118

AB A homogeneous mixture of chloral (I) and an anionic polymerization initiator in an aprotic solvent was dispersed at a temperature above the polymerization threshold temperature and cooled to induce polymerization without agitation and give oriented, high mol. weight polychloral (II) from which tough, nonforaminous, cohesive, infrangible articles are molded. Thus, 75.6 g. pure I was heated to 72° with stirring under N and 77.8 mg. tert-BuLi was added slowly and dissolved. The liquid was cooled at 2°/min. to 59° when cloudiness (formation of II) was noticed. Cooling was continued to 53° and stirring stopped to give a solid gel. On cooling to room temperature a tough solid block of II was obtained. Similar polymers were obtained in PhMe solution also using triethylenediamine and Ph3P initiators. A sheet molding prepared between glass plates was soaked for 4 hrs. in a refluxing mixture of 2871 g. CCl4 and 210 g. PCl5, washed with CCl4, and dried to give a 3.5-mm.-thick sheet with 0.56 ft.-lb./in. notched Izod impact strength, 4800 psi. tensile strength, 11.1% elongation at break, and 322,000 psi. flexural modulus. Fibers were prepared by polymerization in capillary tubes. Examples of other initiators used were LiH, LiAlH4, NaOH, K stearate, pyridine, Et3N, Et3Al, SbCl5, Ph3Bi, Sn octanoate, and bis(hydrogenated tallow)dimethylammonium salts.

IC C08G

INCL 260067000

CC 36 (Plastics Manufacture and Processing)

IT 91-22-5, uses and miscellaneous 97-93-8, uses and miscellaneous
 108-75-8 121-44-8, uses and miscellaneous 121-69-7 124-09-4, uses
 and miscellaneous 151-50-8 288-32-4 542-62-1 554-70-1 556-65-0
 593-29-3 603-32-7 603-33-8 603-35-0 603-36-1 1310-58-3,
 uses and miscellaneous 1310-73-2, uses and miscellaneous 1722-26-5
 1779-49-3 1907-33-1 1912-83-0 7580-67-8 7647-18-9 13400-13-0
 16853-85-3 18428-28-9

RL: CAT (Catalyst use); USES (Uses)

(as catalysts, for polymerization of chloral)

IT 91-22-5, uses and miscellaneous 603-33-8

RL: CAT (Catalyst use); USES (Uses)

(as catalysts, for polymerization of chloral)

RN 91-22-5 CAPLUS

CN Quinoline (CA INDEX NAME)



RN 603-33-8 CAPLUS

CN Bismuthine, triphenyl- (CA INDEX NAME)



L60 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1949:47462 CAPLUS Full-text

DOCUMENT NUMBER: 43:47462

ORIGINAL REFERENCE NO.: 43:8559a-d

TITLE: Experimental chemotherapy of amebiasis
 AUTHOR(S): Anderson, Hamilton H.; Johnstone, Herbert G.; Hansen, Eder L.
 SOURCE: American Journal of Tropical Medicine (1947), 27, 153-60
 CODEN: AJTMAQ; ISSN: 0096-6746
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

AB The effectiveness of a number of drugs in combating *Endamoeba histolytica* infection has been measured in monkeys exptly. infected and in human beings when infection was acquired. The amebicidal, rather than the amebastatic, activity was regarded as the criterion of effectiveness. The drugs were administered orally or parenterally in maximum tolerated doses. In vitro expts. were also conducted. Of 234 agents tested, the following were more active than emetine in vitro: carbarsone oxide (p-ureidophenyl arsenoxide) (I), bis(carboxymethyl) ester (II) of dithio-p- ureidobenzeneearsonous acid and the corresponding bis(o-carboxyphenyl) ester (III), bismarsen, cephaeline isoamyl ether acid phosphate, chaparro amargosa (crystalline fractions of *Castela nicholsoni*), (p- arsenosphenyl)butyric acid, 2-(2-amino-4-arsenosphenoxy)ethanol hydrate, mapharsen, 1-(2,4,5-trimethylbenzyl)-2-aminoethane di-HCl, 1,3-bis(isobutylamino)-2-isothioureapropanol hydrochloride, 9-(dimethylaminophenyl)-10-methyl-3-chloroacridinium chloride, 1,9-dimethylproflavine di-HCl, and subtilin. From in vivo expts. I appeared to be the most effective and in 4 out of 5 patients the drug cleared up the stools when given orally in enteric coated tablets in doses not exceeding 30 mg. II and III were completely effective in monkeys; both have a relatively low systemic toxicity.

CC 11H (Biological Chemistry: Pharmacology)


IT 91-71-4, Benzenearsonous acid, dithio-p-ureido-, bis(o-carboxyphenyl ester) 120-02-5, Acetic acid, (p-ureidophenylarsylenedithio)di-120-02-5, Acetic acid, mercapto-, ester with dithio-p-ureidobenzeneearsonous acid 120-02-5, Benzenearsonous acid, dithio-p-ureido-, bis(carboxymethyl ester) 618-82-6, Sulfarsphenamine, bismuth derivative 2490-89-3, Arsenic, p-ureidophenyl-, oxide 2490-89-3, Carbarsone oxide 12001-47-7, Bismarsen 40553-77-3, Acridine, 3,6-diamino-4,5-dimethyl- 720700-16-3, Acridan, 3,9-dichloro-9-(p-dimethylaminophenyl)-10-methyl- 855195-49-2, Benzoic acid, 4,4'-[(p-ureidophenylarsylene)dithio]di- 857393-22-7, Propylamine, 3-mesityl- 859061-64-6, Pseudourea, 2-[2-diisobutylamino-1-(diisobutylaminomethyl)ethyl]-2-thio- (in amebiasis therapy)

IT 7564-26-3, Quinolinium, 8,8'-(pentamethylenedioxy)bis[1-ethyl-iodide] 114863-72-8, Ammonium, [pentamethylenebis(oxy-o-phenylene)]bis(trimethyl, -diiodide) (pharmacol. of)

IT 12001-47-7, Bismarsen (in amebiasis therapy)

RN 12001-47-7 CAPLUS

CN Methanesulfonic acid, [[5-[bis[[[4-hydroxy-3-[(sulfomethyl)amino]phenyl]arsinidene]bismuthino]arsino]-2-hydroxyphenyl]amino]-, trisodium salt (9CI) (CA INDEX NAME)




●3 Na

IT 7564-26-3, Quinolinium, 8,8'-(pentamethylenedioxy)bis[1-ethyl-iodide]

(pharmacol. of)

RN 7564-26-3 CAPLUS

CN Quinolinium, 8,8'-(pentamethylenedioxy)bis[1-ethyl-, diiodide (8CI) (CA INDEX NAME)




●2 I⁻

FILE 'HOME' ENTERED AT 13:19:52 ON 26 SEP 2008

SEARCH HISTORY



```
=> d stat que l38; d stat que l29; d his nofile
L4 STR
```



```
VAR G1=H/11/13/X
VAR G7=H/11/O
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 11
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21
```

```
STEREO ATTRIBUTES: NONE
L7 35801 SEA FILE=REGISTRY SSS FUL L4
L24 STR
```





```
VAR G1=H/11/13/X/COOH
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 11
CONNECT IS E2 RC AT 15
CONNECT IS E2 RC AT 32
CONNECT IS E1 RC AT 39
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 39

STEREO ATTRIBUTES: NONE

```
L37      869 SEA FILE=REGISTRY SUB=L7 SSS FUL L24
L38      304 SEA FILE=REGISTRY ABB=ON  L37 AND 4/NR
```



L4 STR



```
VAR G1=H/11/13/X
VAR G7=H/11/O
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 11
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

```
STEREO ATTRIBUTES: NONE
L7          35801 SEA FILE=REGISTRY SSS FUL L4
L22         STR
```



```

VAR G1=H/11/13/X/COOH
VAR G7=H/11/OH/22/24
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 11
CONNECT IS E1 RC AT 23
CONNECT IS E2 RC AT 25
CONNECT IS E1 RC AT 27
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11

```

DEFAULT ECLEVEL IS LIMITED




GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L24 STR



VAR G1=H/11/13/X/COOH

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11

CONNECT IS E2 RC AT 15

CONNECT IS E2 RC AT 32

CONNECT IS E1 RC AT 39

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 11

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 39

STEREO ATTRIBUTES: NONE

L28 17584 SEA FILE=REGISTRY SUB=L7 SSS FUL (L24 OR L22)

L29 8061 SEA FILE=REGISTRY ABB=ON L28 AND 2/NR

(FILE 'HOME' ENTERED AT 11:58:21 ON 26 SEP 2008)

FILE 'CAPLUS' ENTERED AT 11:58:36 ON 26 SEP 2008

E US2006-529894/APPS

L1 1 SEA ABB=ON US2006-529894/APPS

D SCAN

E US2005-529894/APPS

L2 1 SEA ABB=ON US2005-529894/APPS

D SCAN

SEL RN

FILE 'REGISTRY' ENTERED AT 11:59:39 ON 26 SEP 2008

L3 16 SEA ABB=ON (148-24-3/BI OR 288-32-4/BI OR 34364-26-6/BI OR
366-18-7/BI OR 4083-64-1/BI OR 566935-65-7/BI OR 57310-75-5/BI
OR 586-98-1/BI OR 614-97-1/BI OR 6425-39-4/BI OR 67-51-6/BI OR
676596-39-7/BI OR 677026-22-1/BI OR 77-58-7/BI OR 91-22-5/BI
OR 91-63-4/BI)
D SCAN
L4 STR
L5 50 SEA SSS SAM L4
L6 885028 SEA SSS FUL L4 EXTEND
L7 35801 SEA SSS FUL L4
SAVE TEMP L7 LEO762FULL/A
E BI/ELS
L8 70589 SEA ABB=ON BI/ELS

FILE 'CAPLUS' ENTERED AT 12:04:10 ON 26 SEP 2008

L9 42497 SEA ABB=ON L7
L10 162907 SEA ABB=ON L8
L11 389 SEA ABB=ON L9 AND L10
L12 0 SEA ABB=ON L1 AND L11
L13 1 SEA ABB=ON L2 AND L11
D SCAN
L14 879 SEA ABB=ON L9(L)CAT/RL
L15 6883 SEA ABB=ON L10(L)CAT/RL
L16 9 SEA ABB=ON L14 AND L15
L17 81358 SEA ABB=ON POLYURETHANES/CT
L18 7 SEA ABB=ON L11 AND L17

FILE 'REGISTRY' ENTERED AT 12:06:40 ON 26 SEP 2008

FILE 'STNGUIDE' ENTERED AT 12:06:55 ON 26 SEP 2008
D QUE NOS L7

FILE 'REGISTRY' ENTERED AT 12:10:27 ON 26 SEP 2008

L19 STR L4
L20 50 SEA SUB=L7 SSS SAM L19
L21 STR L19
L22 STR L4
L23 50 SEA SUB=L7 SSS SAM L22
E 2/NR
L24 STR L21
L25 46 SEA SUB=L7 SSS SAM L24
L26 50 SEA SUB=L7 SSS SAM (L24 OR L22)
L27 35801 SEA SUB=L7 SSS FUL (L24 OR L22) EXTEND
L28 17584 SEA SUB=L7 SSS FUL (L24 OR L22)
L29 8061 SEA ABB=ON L28 AND 2/NR
SAVE TEMP L29 LEO762SUB1/A
L30 2516 SEA ABB=ON L28 AND 4/NR
SAVE TEMP L30 LEO762SUB2/A
D RSD
L31 2542 SEA ABB=ON L28 AND 2 591.79.52/RID
SAVE TEMP L31 LEO762SUB2/A
L32 1368 SEA ABB=ON L30 NOT L31
L33 1394 SEA ABB=ON L31 NOT L30
L34 1148 SEA ABB=ON L30 AND L31
SAVE TEMP L34 LEO762SUB2/A
D QUE
D QUE L24
L35 46 SEA SUB=L7 SSS SAM L24
L36 1385 SEA SUB=L7 SSS FUL L24 EXTEND

```

L37      869 SEA SUB=L7 SSS FUL L24
L38      304 SEA ABB=ON L37 AND 4/NR
          SAVE TEMP L38 LEO762SUB2/A

FILE 'CAPLUS' ENTERED AT 12:26:31 ON 26 SEP 2008
L39      253 SEA ABB=ON L38
L40      37837 SEA ABB=ON L29
L41      2 SEA ABB=ON L10 AND L39
L42      357 SEA ABB=ON L10 AND L40
L43      24 SEA ABB=ON L10 AND L40 AND (L14 OR L15 OR L17)
L44      10824 SEA ABB=ON L9 AND PATENT/DT
L45      523 SEA ABB=ON L9 AND REVIEW/DT
L46      31673 SEA ABB=ON L9 NOT L44
L47      27375 SEA ABB=ON L46 AND PY<2003
L48      8631 SEA ABB=ON L44 AND (PD<20021008 OR AD<20021008 OR PRD<20021008
          )
L49      36153 SEA ABB=ON (L45 OR L47 OR L48)
L50      340 SEA ABB=ON L49 AND L10
L51      1 SEA ABB=ON L49 AND L41
L52      19 SEA ABB=ON L49 AND L43
L53      11 SEA ABB=ON L49 AND (L16 OR L18)
L54      26 SEA ABB=ON (L41 OR L43 OR L16 OR L18)

FILE 'REGISTRY' ENTERED AT 12:30:36 ON 26 SEP 2008
          E A/PCT
          E POLYUR/PCT
L55      80804 SEA ABB=ON POLYURETHANE/PCT

FILE 'CAPLUS' ENTERED AT 13:13:14 ON 26 SEP 2008
L56      47561 SEA ABB=ON L55
L57      2 SEA ABB=ON L56 AND L11
L58      1 SEA ABB=ON L18 AND L57
L59      24 SEA ABB=ON L10 AND L40 AND (L14 OR L15 OR L17 OR L56)
          D QUE L16 NOS
          D QUE NOS L18
          D QUE NOS L57
          D QUE NOS L41
          D QUE NOS L59

FILE 'REGISTRY' ENTERED AT 13:16:46 ON 26 SEP 2008
          D STAT QUE L38
          D STAT QUE L29

FILE 'CAPLUS' ENTERED AT 13:17:07 ON 26 SEP 2008
          D QUE NOS L16
          D QUE NOS L18
          D QUE NOS L57
          D QUE NOS L41
          D QUE NOS L59
L60      26 SEA ABB=ON (L16 OR L18 OR L57 OR L41 OR L59)
          D IBIB ABS HITIND STR L60 1-26
          D IBIB ABS HITIND HITSTR L60 1-26

FILE 'HOME' ENTERED AT 13:19:52 ON 26 SEP 2008
          D STAT QUE L38
          D STAT QUE L29

```

=>